Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 1 
 CLINICAL STUDY PROTOCOL  
 
An open -label, phase 1b multicenter study of IBI308 in subjects with 
advanced/metastatic solid malignancies.  
 
This study will be conducted acc ording to this protocol, including protocol amendments and in 
compliance with Good Clinical Practice, ethical principles, and other applicable regulatory 
requirements 
 
Protocol Number : CIBI308A102  
Clinical Phase : Phase 1b 
IND Number: 136159  
Sponsor: Innovent  Biologics(Suzhou) Co.Ltd  
Version:                                 6 
Effective Date:                       January 7 , 2019 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 2 
  
TABLE OF CONTENTS  
CLINICAL STUDY PROTOCOL  ................................ ................................ .........................  1 
SPONSOR SIGNATURE  ................................ ................................ ................................ ........  7 
INVESTIGATOR AGREEMENT  ................................ ................................ .........................  8 
List of Abbreviations  ................................ ................................ ................................ .................  9 
Synopsis  ................................ ................................ ................................ ................................ ... 11 
Schedule of Events  ................................ ................................ ................................ .................  14 
1. Introduction  ................................ ................................ ................................ ......................  18 
1.1 Background and Rational for Tumor Selection  ................................ ..................  18 
1.2 IBI308  ................................ ................................ ................................ .................  19 
1.3 Rational of the study  ................................ ................................ ...........................  19 
1.3.1  Preclinical Studies  ................................ ................................ ...............................  19 
1.3.2  Clinical Studies  ................................ ................................ ................................ ... 19 
2. Objectives  ................................ ................................ ................................ ........................  22 
2.1 Primary Objectives ................................ ................................ ..............................  22 
2.2 Secondary Objectives ................................ ................................ ..........................  22 
2.3 Exploratory Objective  ................................ ................................ .........................  22 
3. Study Design  ................................ ................................ ................................ ....................  22 
3.1 Scheme of The Study design ................................ ................................ ...............  22 
3.2 Overview  ................................ ................................ ................................ .............  23 
3.2.1  Rationale of Dose Selection  ................................ ................................ ................  23 
3.3 Randomization Procedures  ................................ ................................ .................  24 
4. Study Population  ................................ ................................ ................................ ..............  25 
4.1 Patient Number/Study Sites  ................................ ................................ ................  25 
4.2 Eligibility Criteria  ................................ ................................ ...............................  25 
4.2.1  Overview  ................................ ................................ ................................ .............  25 
4.2.2  Inclusion Criteria  ................................ ................................ ................................  25 
4.2.3  Exclusion Criteria  ................................ ................................ ...............................  26 
4.3 Subject Screening Procedures  ................................ ................................ .............  27 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 3 
 5. Study Intervention  ................................ ................................ ................................ ............  28 
5.1 Study Drug  ................................ ................................ ................................ ..........  28 
5.2 Treatment Compliance and drug accountability  ................................ .................  28 
5.3 Dosage and Drug Administration  ................................ ................................ ....... 29 
5.4 Dosing Procedure and Treatment cycles  ................................ .............................  29 
5.5 Duration of Treatment ................................ ................................ .........................  29 
5.6 Treatment Beyond Disease Progression  ................................ .............................  29 
5.7 Dose Modification and Management of Withholding, Resuming or 
Discontinuation of the Study Drug  ................................ ................................ ......................  30 
5.7.1  Criteria f or Withholding Study Drug  ................................ ................................ .. 30 
5.7.2  Criteria to Resume Treatment  ................................ ................................ .............  31 
5.7.3  Criteria for Drug Discontinuation  ................................ ................................ ....... 31 
5.8 Special Precautions and Clinical Interventions  ................................ ...................  31 
5.8.1  Infusion Reactions  ................................ ................................ ..............................  32 
5.8.2  Extravasation ................................ ................................ ................................ ....... 33 
5.8.3  Immune Related Adverse Events (irAE)  ................................ ............................  33 
5.9 Concomitant Medication  ................................ ................................ .....................  38 
5.10  End of Treatment (EOT)  ................................ ................................ .....................  38 
5.11  Follow -up ................................ ................................ ................................ ............  38 
5.12  Removal f rom Study Treatment and off -Study Criteria  ................................ ..... 39 
5.12.1  Criteria for removal from study treatment  ................................ ...................  39 
5.12.2  Off-Study Criteria  ................................ ................................ ........................  39 
5.13  Pregnancy/Contraception/Nursing  ................................ ................................ ...... 39 
5.13.1  Pregnancy Testing  ................................ ................................ ........................  39 
5.13.2  Contraception  ................................ ................................ ...............................  40 
5.13.3  Use in Pregnancy  ................................ ................................ .........................  40 
5.13.4 Use in Nursing Women  ................................ ................................ ................  41 
6. Study assessment and Evaluations  ................................ ................................ ...................  41 
6.1 Specimen Collection and Evaluations  ................................ ................................  41 
6.1.1  Pharmacokinetics (PK)  ................................ ................................ .......................  41 
6.1.2  Immunogenicity  ................................ ................................ ................................ .. 41 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 4 
 6.1.3  Biomarkers  ................................ ................................ ................................ ..........  41 
6.1.4  Safety Laboratory Evaluations  ................................ ................................ ............  43 
7. Data Collection and Management  ................................ ................................ ....................  43 
7.1 Protocol Deviations  ................................ ................................ .............................  44 
7.2 Publication and Data Sharing ................................ ................................ ..............  44 
8. Human Subject Protection and Regulatory Oversight  ................................ .....................  44 
8.1 Informed Consent Processes and Documentation ................................ ...............  44 
8.2 Institutional Review Board Approval  ................................ ................................ . 45 
8.3 Case Report Forms (CRFs)  ................................ ................................ .................  45 
8.4 Confidentiality and Privacy  ................................ ................................ ................  46 
8.5 Conflict of Interest  ................................ ................................ ..............................  46 
9. Safety Reporting  ................................ ................................ ................................ ..............  47 
9.1 Definitions ................................ ................................ ................................ ...........  47 
9.2 Causality AE  ................................ ................................ ................................ ....... 47 
9.3 Categori zations of AEs  ................................ ................................ .......................  48 
9.4 Reporting of SAEs  ................................ ................................ ..............................  49 
9.5 IRB Reporting  ................................ ................................ ................................ ..... 49 
9.6 Report ing of Pregnancy  ................................ ................................ ......................  49 
10. STATISTICAL  CONSIDERATIONS AND EVALUATION OF RESULTS  .. 50 
10.1  General Statistical Consideration  ................................ ................................ ........  50 
10.2  Data Analysis  ................................ ................................ ................................ ...... 51 
10.2.1  Pharmacokinetic Data  ................................ ................................ ..................  51 
10.2.2  Immunogenicity  ................................ ................................ ...........................  51 
10.2.3  Efficacy  ................................ ................................ ................................ ........  51 
10.3  Determi nation of Sample Size  ................................ ................................ ............  51 
10.4  Subject Replacement Policy  ................................ ................................ ...............  51 
10.5  Safety Evaluations  ................................ ................................ ..............................  52 
10.6  Efficacy Evaluations  ................................ ................................ ...........................  52 
10.7 Population Analysis  ................................ ................................ ............................  52 
10.7.1  Safety Population  ................................ ................................ .........................  52 
10.7.2  Efficacy Population  ................................ ................................ ......................  53 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 5 
 10.7.3  PK Population  ................................ ................................ ..............................  53 
10.8  Tabulation of Individual Participation Data  ................................ .......................  53 
11. Study management  ................................ ................................ ..............................  53 
11.1  Quality Assurance and Quality Control  ................................ ..............................  53 
11.2  Clinical Monitoring Plan ................................ ................................ .....................  54 
11.3  Study Closure  ................................ ................................ ................................ ...... 54 
12. REFERENCES  ................................ ................................ ................................ ... 56 
13. GENERAL APPENDICES  ................................ ................................ .................  57 
13.1  Appendix 1 Eastern Cooperative Status Oncology Group Performance Status 
Score  ................................ ................................ ................................ .............................  57 
13.2  Appendix 2 Response Evaluation Criteria in Solid Tumors (RECIST) Version 
1.1 ................................ ................................ ................................ .............................  58 
13.3  Appendix 3 modified RECIST 1.1 for immune based therapeutics (iRECIST)  . 60 
 
  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 6 
 LIST OF TABLES  
Table -1. Schedule of Events  ................................ ................................ ................................ .... 14 
Table -2. Details of Sampling for Pharmacokinetics (PK)  ................................ .......................  17 
Table -3 Clinical Trials Conducted in China: Current status (cut -off date: Oct 30, 2017) ....... 20 
Table -4. Summary of AEs in subjects receiving IBI308 treatment  ................................ .........  21 
Table -5. Study population, sample size and treatment dose.  ................................ ...................  29 
Table -6 Management of Infusion -Related Reactions/Hypersensitivity Reactions (NCI 
CTCAE Grade)  ................................ ................................ ................................ ........................  32 
Table -7  Management of Gastrointestinal irAEs  ................................ ................................ ..... 33 
Table -8  Management of Hepatic irAEs  ................................ ................................ ..................  34 
Table -9 Management of Dermatological irAEs.  ................................ ................................ ...... 35 
Table -10  Management of Pulmonary irAEs.  ................................ ................................ ..........  36 
Table -11 Management of Renal irAEs.  ................................ ................................ ...................  37 
 
  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 7 
 SPONSOR SIGNATURE  
 
Study Title: An open -label, phase 1b multicenter study of IBI308 in subjects with 
advanced/metastatic solid malignancies  
 
Study Number:  CIBI308A102  
 
Protocol  Version : Version 6, Jan 07, 201 9 
 
 
Person authorized to sign the protocol and protocol amendment(s) for the Sponsor, Innovent 
Biologics (Suzhou) Co. Ltd.  
 
 
Signature ______________________________________________________________  
 
Date__________________________________________________________________  
  PRINTED NAME  Kerry Levan Blanchard  
TITLE  Chief Science Officer  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 8 
 INVESTIGATOR AGREEMENT  
Protocol No.: CIBI308A102  Version Date:  V 6, Jan 07, 201 9 
I have read the protocol  CIBI308A102  and Investigators’ Brochure for study conduct and 
regarding the risks and potential benefits of the trial. I agree to conduct the protocol in accordance 
with Good Clinical Practices (ICH -GCP ), Federal regulations, and state and local laws to maintain 
the protection of the rights and welfare of study participants.   
I certify that I, and my research study staff, have received adequate  training to conduct this 
research protocol.  
I agree to maintain accurate and adequate records in accordance with  institutional, company , 
Federal, state and local laws and regulations.  
 
 
Principle Investigator  
 
Name (printed)______________________________________________________________  
 
Signature ___________________________________________________________________   
 
 
 
 
 
 
 
 
  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 9 
 List of Abbreviations  
 
AE adverse event  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
ANC  absolute neutrophil count  
AST  aspartate aminotransferase  
AUC  area under the curve  
aPTT  Partial thromboplastin time  
BUN  blood urea nitrogen  
CBC  complete blood cell (count)  
CR Complete  Response  
CRF  case report form  
CT Computerized T omography  
CTC AE Common Terminology Criteria for Adverse Events  
DFS disease -free survival  
DLT  dose limiting toxicity  
DSMC  Data and Safety Monitoring Committee  
ECOG  Eastern Cooperative Oncology Group  
EOT  End of treatment  
EOI End of Infusion  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
HBeAg  Hepatitis B “e” antigen  
HBV  hepatitis B virus  
HCT  hematocrit  
HCV  hepatitis C virus  
HGB  hemoglobin  
HIV human immunodeficiency virus  
ICH International Conference on Harmonization  
IND investigational new drug application  
INR International normalized ratio  
IP investigational product  
IRB Institutional Review Board  
IRRC  
irAE  Independent Radiology Review Committee  
immunotherapy -related adverse events  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 10 
 IV intravenous  
LDH  lactate dehydrogenase  
LFT liver function test  
MedDRA  Medical Dictionary for Regulatory Activities  
MRI  magnetic resonance imaging  
NCI National Cancer Institute  
NSCLC  Non-Small Cell Lung Cancer  
ORR  overall response rate  
PD disease progression  
PK pharmacokinetics  
PO Per os (by mouth, orally)  
PR partial response  
PT Prothrombin time  
PD-1 programmed cell death protein 1  
PD-L1 programmed death -ligand 1  
RBC  red blood cell (count)  
RECIST  Response Evaluation Criteria in Solid Tumors  
SD stable disease  
SD standard deviation  
TMB  Tumor Mutation Burden  
ULN  upper limit of normal  
WBC  white blood cell (count)  
 
 
 
 
 
 
 
 
 
  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 11 
 Synopsis  
 
Title:  An Open -label, Phase 1b Multicenter Study of  IBI308 in Subjects 
with Advanced/Metastatic Solid Malignancies  
Sponsor  Innovent Biologics (Suzhou) Co. Ltd.  
Study Drug  IBI308  
Clinical Trial Phase  Phase 1b 
Proposed Indication  Advanced/metastatic solid malignancies  
Objectives:  
 Primary  
• To evaluate preliminary anti -tumor activity (overall 
response rate, ORR) of IBI308 monotherapy  in subjects 
with advanced/metastatic  solid  malignancies.  
 Secondary  
• To measure progression -free survival rate (PFS).  
• To measure duration of response (DOR).  
• To measure overall survival rate (OS).  
• To obtain safety and toxicity data.  
• To further evaluate pharmacokinetics ( PK) of IBI308 . 
• To further evaluate immunogenicity of IBI308.  
 
Exploratory Objectives  
• To explore the relationship between baseline markers 
(PD-L1, TMB  etc.) and clinical response . 
• To explore the relationship between exposure and 
efficacy/safety.  
• To assess the impact of ADA on PK, efficacy/safety . 
Study Population:  ≥18 years, have a histologically or cytologically confirmed 
advanced/metastatic solid tumor and have progressed on 
available standard therapies or for which no standard therapy 
exists.  
Number of Subjects 
planned  Up to  40 subjects  with advance d/metastatic endometrial cancer 
(EC)  will be enrolled in cohort  2. The original planned cohort 1 
with 60 subjects with advanced/metastatic  cancer and high tumor 
mutational burden (TMB)  has stopped enrolling at the time of the 
protocol amend ment . 
Number of Study 
Centers Planned  Approximately 15 study sites located in the United States. 
Additional sites may be added if necessary.  
Description of Study 
Intervention:  This is an open -label, phase 1b  multicenter study of IBI308 in 
subjects with advanced/metastatic solid malignancies. Patients 
will be recruited for  2 cohorts : 
 Cohort 1: Advanced/metastatic cancers with TMB>10 
mutations per megabase ( mut/Mb ).  This enrollment of this 
cohort has been stopped  per sponsor’s communication with 
the sites. For patients who have already enrolled in this 
cohort, treatment and monitorin g will be conducted as 
stipulated by the protocol.   The patients will remain on study 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 12 
 until disease progression or intolerable toxicity, death, 
withdrawal of consent, or end of study, whichever occurs 
first. 
 Cohort  2: Advanced/ metastatic endometrial cancer  (N=40) 
Please see Table -5 for sample sizes.  A fixed  dose of 200 mg 
IBI308 will be administered as IV infusion  for every three weeks 
(Q3W)  to the patients  until disease progression  or intolerable 
toxicity, death, withdrawal of consent, or end of study, whichever 
occurs first.  
Study participation 
Duration:  The maximum treatment duration is 2 years.  
Pharmacokinetic (PK) 
evaluations  PK of IBI308 will be investigated extensively: PK will be 
assessed at predose , within 5 min after  the end of infusion 
(EOI), at 1, 6, 24, 48, 168, 336 hours  post EOI in Cycle 1 , 
predose in Cycle 2 and every other  cycle thereafter  for the first 
12 cycles , and at 30 days follow -up visit  for the first 6 subjects 
in cohort 1 and first 12  subjects  in cohort 2 . 
PK will be sparsely assessed at predose in Cycle 2 and every 
other cycle thereafter  for the first 12 cycles, and at 30 days 
follow -up visit for other subjects .   
The results of these analyses, if performed, may be reported 
separately.  
Safety Evaluations  Safety will be assessed by physical examinations, vitals, ECG, 
laboratory tests, AE monitoring, and concomitant medication 
usage monitoring. AEs are graded according to the CTCAE 
v4.03. Investigators will report whether an AE is potentially 
immune related (irAE). irAEs are defined as AEs of unknown 
etiology potentially associated with an immune phenomenon. 
Follow up for SAEs , which are assessed as at least possibly 
related late irAEs , will be followed up to 3 months after th e last 
dose of IBI308.  
Efficacy Evaluations  Tumor assessment will be performed at baseline, every 2 cycle s, 
and at the end of treatment by the investigator per RECIST v1.1. 
Efficacy evaluations will include the following: computed 
tomography (CT) , magnetic resonance imaging  (MRI) , physical 
examination, and other procedures as necessary. If a patient is 
classified as having disease progression at a post -baseline tumor 
assessment, then confirmation by a second scan within 4 -6 weeks 
in the absence of r apid clinical deterioration is required.  
Anti-cancer activity parameters that will be assessed include 
determination of the following:  
1) Best overall response [complete response (CR), partial 
response (PR), stable disease (SD), or progressive disease]  
2) Objective response rate (ORR) (CR + PR)  
3) Duration of response (DOR) or duration of SD  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 13 
 4) Disease control rate (DCR) (CR, PR or SD)  
5) Progression -free survival (PFS) and overall survival (OS) 
efficacy evaluations  
Immunogenicity  Blood samples for anti-drug antibody (ADA)  analyses will be 
collected within 24 hours before start of infusion in Cycle 1 and 
Cycle 2 and then in every other subsequent cycle, and at the 
Safety Follow -up Visit or until start of a new anti -cancer therapy, 
whichever occurs fi rst.  
Statistical Analysis:  Summary statistics will be presented by cohort as well as overall 
for the trial. The number of subjects presenting with adverse 
events  will be summarized by cohort and overall for the trial. 
Safety and tolerability will be evaluated by AEs/irAEs, laboratory 
assessments, vital signs, 12 -lead electrocardiograms, physical 
examination, ECOG PS, and concomitant medication usage, 
using the safety analysis set. For laboratory data, changes over 
time will be described using descript ive statistics, and the 
percentage of subjects with values outside the normal range will 
be presented.  
All PK, immunogenicity, and safety data will be summarized 
using descriptive statistics (number of subjects, mean, median, 
standard deviation, minimum, and maximum) for continuous 
variables and using frequencies and percentages for discrete 
variables.   
ORR and the associated 2 -sided 95% exact confidence limits will 
be provided. The proportion of subjects who have experienced 
best response as CR, PR, SD o r disease progression ( PD) will be 
calculated. PFS and OS data will be analyzed by Kaplan -Meier 
method.  
 
 
 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 14 
 Schedule of Events  
Table -1. Schedule of Events  
Study Day/Visit 
Day Screening -
28 to 0  
(±  3 Day)  Cycle 1 Day 1  Each Subsequent Cycle  
Day1 (±  3 Day)  EOT  
Within 7 days16 
 (±3 Days)  Safety FU 30 Days  after 
last dose  
(±  7)17 Survival FU (± 7) 
Every 3 mo nths after last 
dose18 
Informed consent  X      
Inclusion/Exclusion 
Criteria  X      
Medical History  X      
Safety Assessment   
Vital Signs 1 X X X X X  
Physical 
Examination  X X X X X  
ECOG 
Performance 
Status  X X X X X  
Disease -Specific 
Staging Criteria2 X      
AE assessment  X X X X X  
Concomitant 
medications  X X X X X  
CBC w/ Diff 3 X X X X X  
Blood chemistry 4 X X X X X  
Thyroid Function 
Tests 5 X  X X X  
Coagulation 6  X      
Pregnancy test 
(HCG)7 X    X  
Hepatitis and HIV 
screen8 X      
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 15 
 ECG (12 Lead)9 X X X X X  
Urine Analysis  X  X X X  
Efficacy Assessments   
Imaging (CT or 
MRI)10 X every 2 cycles and at EOT    
Cardiac 
Assessment 
(ECHO, MUGA)11 X      
Bone scan19 X      
Administration of Investigational drug   
Administration of 
IBI308   X X    
Biomarker Assessments   
Tissue12 X      
Blood  samples13  X X  X  
PK and Immunogenicity   
PK14 (see Table 2)        
ADA15  X X  X  
EOT: end of treatment  
 
1 Baseline conditions  
2 Disease -specific staging criteria (for CRF purposes, e.g.: TNM  classification  and etc.) 
3 Including CBC with differential and platelet count  performed within 7 days prior to first dose (do not repeat Cycle 1 Day 1 CBC, if screening CBC is within 7 days of dosing ) 
and 72 hours prior following doses on the schedule  
4 Including alkaline phosphatase, ALT/AST, total bilirubin, BUN, creatinine, total protein, albumin, fasting glucose, potassium , sodium, chloride, uric acid, LDH, fasting lipid 
panel (LDL, tot al chol esterol, triglycerides) , amylase and lipase performed within 7 days prior to first dose (do not repeat Cycle 1 Day 1 Blood Chemistry, if screening Blood  
Chemistry is within 7 days of dosing ) and 72 hours prior following doses on the schedule  
5 Thyroid function tests include Thyroid stimulation hormone (TSH), Free T3 and T4  
6 Including aPTT/INR  performed within 7 days prior to first dose  at day 1 on a schedule  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 16 
 7 Pregnancy test needs to be performed within 72 hours before Cycle 1 dosing  and at first Safety Fo llow-up visit  
8 Including HBsAg, HBsAb, HBcAb, Hep C RNA , HIV screen  
9 12-lead ECG  on screening,  72 hours prior  each dose , EOT and at first Safety Follow -up visit   
10 Tumor imaging (either CT or MRI , with preference for CT ) will be performed at screening, every 2  cycles and EOT . The same imaging technique should be used in a patient 
throughout the study. Tumor assessment should be performed according to RECIST 1.1 and to iRECIST 1.1  
11 Cardiac Assessments Echocardiogram (ECHO) and/or multiple -gated acquisition scan ( MUGA) at screening phase , and as clinically indicated afterwards . 
12 May be archival or recent sample. Separate ICF is needed for collecting fresh tumor tissue biopsies. 1 formalin -fixed paraffin embedded tumor tissue block, or minimum of 
10 FFPE unstained slides are needed. Evaluations include but are not limited to PD -L1 and TIL, please refer to 6.1.3 section for details. Specific instructions for tissue collection 
and shipment are provided in the procedures manual.  
13 Collected prior to first dose  and every 2 cycles  at predose until the Safety Follow -up Visit . Evaluations  include but are not limited to factors induced by IFNγ signaling, 
antibodies to tumor -associated antigens, and soluble PD -L1 (PD -L1), please refer to 6.1.3 section for details. Specific instructions for sample collection and shipment are 
provided in the proc edures manual.  
14 Please see details in specific PK  (Table -2).  
15 Blood samples for anti -drug antibody (ADA) analyses will be collected within 24 hours before start of infusion in Cycle 1 and Cycle 2 and then in every other subsequent 
cycle, and at the S afety Follow -up Visit  or until start of a new anti -cancer therapy, whichever occurs first.  
16 EOT visit should be completed within 7 days (± 3 Days) if investigator decides to end the treatment for subject. If the physic al exams, lab tests and other relevant events 
which should be performed on the EOT have done within 7 days of next planned visit after previous dose of study medicine, the se results could be recorded as EOT visit; if the 
above scheduled events have done within 21 to 30 days after the last dose of study medicine, these results could be recorded as the safety FU visit.  
17 The mandatory Safety Follow -Up Visit should be conducted approximately 30 days  after the last dose of study therapy or before the initiation of a new anti-cancer treatment, 
whicheve r occurs first. Patients who are discontinued from the study due to an unacceptable drug -related adverse event will be followed until the resolution of the AE to Grade 
0-1 or stabilization or until beginning of a new therapy for their cancer, whichever occ urs first.  
18 After the Safety Follow -UP visits, subjects will have survival follow -ups every 3 months by clinical visits or telephone calls, until death, loss -to-follow -up, withdrawal of 
consent, or study termination by sponsor.  
19 Bone scan should be performe d according to local clinical practice guideline by investigators’ decision  
 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 17 
 Table -2. Details of Sampling for Pharmacokinetics  (PK)   
 Screening  Treatment  Safety FU  
30 Days  
(±7) Cycle 1  2Cycle 2 and  
Additional Cycles  
(21 Days ± 2 Days)  
Day -28~-1 1 2 3 8 15 1  
  Predose    Post-
dose      Predose     
1Time 
Points   -1h infusion  Immediately 
at end of 
infusion  1h 6h 24h 48h 168h  336h  -1h infusion  Immediately 
at EOI  
Window     +5min  ± 5min  ± 15mi
n ±1h ±2h ±8h ±12h   +5min   
IBI308    X         X   
4PK  X  X X X X X X X X 2   X 3 
Please note:  
1. Sample collection must be from opposite arm to that used for study drug infusion.  
2. Cycle 2 and subsequently every other cycle  for the first 12 cycles.  
3. PK assays should be performed at the mandatory  end of study visit.  
4. PK will be intensively assessed at predose, within 5 min after the end of infusion (EOI), at 1, 6, 24, 48, 168, 336 hours post EOI in Cycle 1, predo se in 
Cycle 2 and every other cycle thereafter for the first 12 cycles, and at 30 days follow -up visit for the first 6 subjects in cohort 1 and  first 12 subjects in  
cohort 2. PK will be spars ely assessed at predose, within 5 min after the end of infusion (EO I) in cycle1, predose in Cycle 2 and every other cycle thereafter 
for the first 12 cycles, and at 30 days follow -up visit for other subjects.  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 18 
 1. INTRODUCTION  
1.1 Background  and Rational for Tumor Selection   
Recently emerging data has shown, t hat immunotherapeutic treatment with check point 
inhibitors is efficient and well tolerated, with a favorable safety profile and less toxicity as 
compared to conventional chemotherapy. The interaction between the programmed cell death 
protein 1 (PD -1) and its ligands (programmed death -ligand 1 (PD -L1) and programmed death -
ligand 2 (PD -L2), plays an important role in maintaining the balance between immune 
activation and tolerance, potentially including tumor tolerance. Blocking the interaction 
between PD -1 and PD -L1, has been reported to have antitumor effect s in many malignancies . 
A number of checkpoint inhibitors including PD -1 or its ligand (PD -L1), have been approved 
by FDA for the treatment of multiple cancers including non -small cell lung cancer (NSCLC) , 
melanoma, classical Hodgkin lymphoma (cHL), urothelial carcinoma, renal cell carcinoma 
(RCC), adult and pediatric microsatellite instability -high cancer (MSI -H) or mismatch repair  
deficient (dMMR) metastatic colorectal cancer (mCRC) , hepatocellular carcinoma (HCC),  
gastric cancer, and recurrent or metastatic head and neck squamous cell cancer  (HNSCC) 
(OPDIVO®; KEYTRUDA®).   
Endometrial cancer (EC)   
EC is the 4th most common maligna ncy among women and the 6th leading cause of death in 
2017 . It is the most common gynecologic malignancy in the United States, with an estimated 
61,380 new cases and 11,000 deaths in 2017  (ACS , 201 6). The incidence of EC is increasing 
annually by an estimated 1 -2%. Obesity is a strong risk factor for the development of EC, 
accounting for approximately 50% of cases in Europe  and the United States; it also has been 
associated with a  relative increased risk of death of up to 6.2 5. While most ECs present at an 
early stage, approximately 25 % of early stage and more than 50 % of advanced stage cancers 
will recur.  
 
Current adjuvant therapies for advanced EC patients are not very effective and there are 
limited options for patients with metastatic  disease. Patients with advanced stage disease at 
the time of diagnosis have a high risk for recurrence. The median survival after recurrence is 
ten months and the five -year overall survival for patients who have recurred is less than 15%. 
Unfortunately, recurrent disease  is generally not curable, and response rates for hormone 
therapy  are in the 15 -20 % range  (Lee et al., 2014 ). Therefore , efforts in finding effective 
treatments for this population need to be pursued. In a Phase1 Study ( [STUDY_ID_REMOVED] ) in 
patients  with EC  after failure of prior systemic treatment , the confirmed  response rate to 
pembrolizumab was 13 %, demonstrating a promising activity in this heavily pretreated PD -
L1 positive EC patients .   
 
Tumor mutation burden ( TMB ) 
TMB was defined as the number of somatic, coding, base substitution, and indel mutations per 
megabase of genome examined. Retrospective data suggest that mutational load may 
potentially predict response more robustly than PD -L1 IHC, presence of tumor infiltrating 
lymphocytes, or clinical variables.  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 19 
 TMB-h cancer types, NSCLC, melanoma , bladder cancer  patients and other indications where 
PD-1 is thought to play a role in tumor immune evasion, were  allowed to be enrolled in this 
IBI308 study.  The sponsor has made strategic decisions to stop enrolling into this cohort. This 
decision was not related to an y safety or ethic concerns.  
1.2 IBI308  
IBI308 is a novel PD -1 antagonist that is being developed for the treatment of various tumors. 
It binds to and neutralizes PD -1 receptor mediated immune suppressive signals on T cells, and 
activates human immune response to kill tumor cells.  
 
1.3 Rational of the study  
1.3.1 Preclinical Studies  
Comprehensive nonclinical studies had been conducted to study the pharmacological 
activities, pharmacokinetic -pharmacodynamics (PK/PD) relationships and safety profiles of 
IBI308. The in vivo  nonclinical toxicology (4 -week and 26 -week) and pharmacokinetic 
studies in cynomolgus monkeys suggest that IBI308 is safe for use in clinical studies in cancer 
patients. Additional in vitro  and in vivo  pharmacology and toxicology studies conducted 
using nivolumab (an approved anti -PD-1 mAb) as a comparator further support the safety 
and efficacy of IBI308. In these studies, similar profiles were observed for IBI308 and 
nivolumab in terms of binding affinity, blockade of PD -1 receptor and ligand binding, 
enhancement of T cell activation in an allogenic MLR assay, anti -tumor activity in a mouse 
xenograft model, tissue cross reactivity, and cytokine release.  
Refer to the IB for more detailed in formation on preclinical studies of IBI308.  
 
1.3.2 Clinical Studies  
IBI308 was first developed in China intended for treating advanced/metastatic tumors. In China , 
Innovent  has completed phase 1 dose escalation trials, and currently is conducting 3 Phase 2 
trials and 1 Phase 3 trial  for IBI308  (Table -3). Innovent filed a BLA for IBI308 in China for 
recurrence / refractory Hodgkin's lymphoma  in early December of 2017. Refer to the IB for 
more detailed safety and efficacy information on clinical studies of IBI308.  
As of October 30, 2017, a total of 267 advanced cancer patients received ≥1 dose of study drug, 
of whom 40.45% completed 5 or more treatment  cycles with a median duration of 12 weeks 
(9.0 to 17.9), and maximum of 23 cycles . Among the 267 patients who received IBI308, 258 
patients were treated at the 200 mg fixed  dose as monotherapy or in combination with 
chemotherapeutic agents, 6 patients rec eived an equivalent (3 mg/kg, n=3) or higher dose than 
200 mg (10 mg/kg, n=3) . Only 3/267 patients received a dose less than 200 mg (1 mg/kg, n=3). 
Overall, the 200 mg fixed  dose was well tolerated in patients with various advanced cancers.  
 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 20 
 Table -3 Clinical Trials Conducted in China: Current status (cut -off date: Oct 30, 2017)  
 
Study  Disease  IBI308 Dose  Subject 
Number  
    
CIBI308A101 
Phase  Ia Advanced s olid tumor  4 dosage level:   1 mg/kg, 3mg/kg, 
200mg, 10mg/kg  12 (n=3 
per 
cohort)  
CIBI308A101 
Phase Ib Cohort  A: Advanced m elanoma  200mg Q3W  20 
Cohort  B: Digestive or neuroendocrine 
tumors, failed in standard treatment  200mg Q3W  74 
Cohort  C: Advanced NSCLC, failed in 
standard treatment  200mg Q3W  26 
Cohort  D: Advanced NSCLC, Naï ve 
patients  200mg Q3W  
pemetrexed  500 mg/m2 and cisplatin 
75 mg/m2 Q3W  7 
Cohort  E: Advanced squamous cell 
NSCLC, never received systemic 
treatment  200mg Q3W  
gemcitabine 1250 mg/m2 IV and 
cisplatin 75 mg/m2 IV Q3W  1 
CIBI308B201  
Phase 2 
(ORIENT -1)  
Recurrence / refractory Hodgkin's 
lymphoma  200 mg Q3W  95 
CIBI308A201  
Phase 2 
(ORIENT -2) Second -line esophageal squamous cell 
carcinoma  200 mg Q3W  15 
CIBI308C301  
Phase 3 
(ORIENT -3) Advanced or metastatic squamous 
NSCLC who have failed platinum -based 
chemotherapy  200 mg Q3W  2 
CIBI308D201  
Phase 2 
(ORIENT -4) Recurrence / refractory NK/T cell 
lymphoma  200 mg Q3W  15 
Total number    267 
The safety  analysis included 267 subjects treated with IBI308, among whom 220 (82.4%) had 
at least one adverse event (AE) and 80.1 % had at least one treatment -emerged  AEs (TEAE) 
during treatment  (Table -4). The most common AEs were fever (27.7%), anemia (13.9%) and 
increased aspartate aminotransferase (11.2%), fatigue (10.5%), decreased white blood cell 
count (9.4%), elevated alanine aminotran sferase (8.2%), albuminuria (7.5%), constipation 
(7.1%), rash (6.4%), elevated serum bilirubin (6.4%), hypoalbuminemia (6.0%), reduced 
platelet count (6.0%), decreased appetite (5.6%), and upper respiratory tract infection. The 
incidence of IBI308 -related TEAEs was 63.7%, of which TEAE ≥3 grade was 10.1%. The most 
common IBI308 -related TEAEs  (Classified by PT) were fever (20.6%), elevated aspartate 
aminotransferase (7.1%), fatigue (6.7%), elevated alanine aminotransferase (6.4%)  and 
elevated b ilirubin (5.2%) , rash (5.2%) .  
A total of 12 out of 267 patients experienced adverse events with special interest (AESI). 
Pneumonia accounts for 2.2% of all A ESIs  (all were immune reaction related pneumonia).  The 
incidence of Severe AEs (SAEs) during treatment was  12.7 % (34 cases), and 6.0 % of the 
SAEs were considered possibly related to IBI308  (Table -4). The most common SAEs included 
pulmonary infection (1.9%), pneumonia (1.5%), fever  (0.8%), upper gastrointestinal bleeding 
(0.8%), and dysphagia (0.8%).   
The above AEs were also commonly seen from the FDA approved Nivolumab and 
Pembrolizumab . The 200mg f ixed dose was well tolerated in patients with various  advanced 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 21 
 cancers  and the overall safety profiles of IBI308 were similar to those of the FDA approved 
anti-PD-1 products.  
Refer to the IB for more detailed safety information on clinical studies of IBI308.  
Table -4. Summary of AEs in subjects receiving IBI308 treatment  
index  CIBI308A101  
(N = 140)  CIBI308A201  
Total (N = 15)  CIBI308B201  
Total (N = 95)  CIBI308C301  
Total (N = 2)  CIBI308D201  
Total (N = 15)  CIBI308  
(N = 267)  
Adverse Events 
(AE)  106 
(75.7%)  12 (80.0%)  86 (90.5%)  1 (50.0%)  15 
(100.0%)  220 
(82.4%)  
Treatment emergent 
adverse events 
(TEAE)  105 
(75.0%)  10 (66.7%)  84 (88.4%)  1 (50.0%)  14 (93.3%)  214 
(80.1%)  
IBI308 treatment  
related AE (TRAE)  79 (56.4%)  8 (53.3%)  70 (73.7%)  1 (50.0%)  12 (80.0%)  170 
(63.7%)  
≥ Grade 3 TEAE s 33 (23.6%)  4 (26.7%)  12 (12.6%)  1 (50.0%)  2 (13.3%)  52 
(19.5%)  
≥ Grade 3 TRAEs  15 (10.7%)  2 (13.3%)  9 (9.5%)  0.0 1 (6.7%)  27 
(10.1%)  
Immune -related 
AEs 22 (15.7%)  3 (20.0%)  22 (23.2%)  0.0 1 (6.7%)  48 
(18.0%)  
Special interests of 
AEs (AESIs)  6 (4.3%)  3 (20.0%)  3 (3.2%)  0.0 0.0 12 
(4.5%)  
SAEs  22 (15.7%)  2 (13.3%)  8 (8.4%)  1 (50.0%)  1 (6.7%)  34 
(12.7%)  
SAEs  related to 
IBI308  9 (6.4%)  1 (6.7%)  6 (6.3%)  0.0 0.0 16 
(6.0%)  
AEs leading to 
permanent  
treatment 
discontinuation  10 (7.1%)  1 (6.7%)  1 (1.1%)  0.0 0.0 12 
(4.5%)  
AEs leading to 
death  2 (1.4%)  1 (6.7%)  0.0 0.0 1 (6.7%)  4 
(1.5%)*  
AEs leading to 
terminate the study  8 (5.7%)  1 (6.7%)  0.0 0.0 1 (6.7%)  10 
(4.5%)  
Important TEAE  78 (55.7%)  7 (46.7%)  57 (60.0%)  1 (50.0%)  9 (60.0%)  152 
(56.9%)  
 a CTCAE version 4.03 for severity grading. Adverse events of death level 5.  
 b Serious adverse events include any death, life -threatening, hospital -related or prolonged hospital stay, 
adverse events that result in continuing or major disability / incapac ity, congenital anomalies / birth defects, 
or other major medical hazards.  
 
  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 22 
 2. OBJECTIVES  
2.1 Primary Objectives  
To evaluate preliminary anti -tumor activity (overall response rate, ORR) of IBI308 as a single 
treatmen t agent in selected populations  
 
2.2 Secondary Objectives  
 To measure progression -free survival rate (PFS) . 
 To measure duration of response (DOR).  
 To measure overall survival rate (OS) . 
 To obtain toxicity data . 
 To further evaluate PK parameters.  
 To further evaluate immunogenicity of IBI308.  
2.3 Exploratory  Objective  
 To explore the relationship between baseline markers ( TMB ) and clinical response  
 To explore the relationship between exposure and efficacy/safety  
 To assess the impact of ADA on PK, efficacy/safety  
 
3. STUDY DESIGN  
3.1 Scheme of The Study design  
 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 23 
  
 
3.2 Overview  
This is an open -label, phase 1b multicenter study of IBI308 in subjects with 
advanced/metastatic solid malignancies . The trial  will recruit  2 cohorts : cohort 1 consisting of  
advanced/metastatic cancer patients with TMB>10 mut/Mb , and cohort 2 con sisting of 
advanced endometrial cancer  patients  (refer to Study Design Scheme , and Table -5 for sample 
sizes) . Sponsor has made strategic decisions  to stop enrollment in  cohort  1 in this protocol 
amendment . In each cohort a fixed dose of 200 mg  IBI308 will be  administered  Q3W  to the  
patients. Additional cohorts may be added to this study via a  new IND package or will be added 
with a protocol amendment submission during the clinical trial stage.   
3.2.1 Rationale of Dose Selection  
Innovent  would like to initiate the Phase 1b expansion study with a fixed  dose of 200 mg  
IBI308  Q3W , based on all nonclinical and clinical data obtained from Chinese studies, as well 
as the FDA approved clinical dose of similar anti -PD-1 products.   
 The no observe d adverse effect level (NOAEL) of 200 mg/kg observed in the pivotal 4 -
week toxicity study in monkeys was used to determine the maximum recommended 
starting dose (MRSD) for IBI308 .  Applying a 10 -fold safety margin, the corresponding 
MRSD is 20 mg/kg (1/10 of NOAEL). The proposed Phase 1b  dose (200 mg ) is 

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 24 
 equivalent to 3 mg/kg given an average body weight of 70 kg. This dose is 6 -fold lower 
than the MRSD.  
 A Phase 1 dose -escalation (3+3) study at doses of 1 mg/kg, 3 mg/kg, 200 mg ( fixed  dose), 
and 10 mg/kg Q 3W was completed in Chinese patients with advanced malignancies 
(N=12). A Phase 1 dose expansion (200 mg as monotherapy or in combination with other 
chemotherapies in various cancer diseases) is ongoing in China. There were no DLT at  
any dose up to includi ng 10mg/kg in the completed Phase 1a study. IBI308 was generally 
well tolerated after single and multiple dose administration in patients with advanced 
cancers.  
 Currently, there are 5 clinical studies with IBI308 in China. As of October 30, 2017 
(cutoff d ate), a total of 267 advanced cancer patients received ≥1 dose of study drug, of 
whom 91.76 received ≥2 cycles, 79.40% received ≥3 cycles, 57.68% received ≥4 
cycles, and 40.45% received ≥5 cycles of dosing. Among the total of 267 patients who 
received at least one dose of IBI308, 258 patients were treated at the 200 mg fixed  dose 
as monotherapy or in combination with chemotherapeutic agents. Overall, the 200 mg 
fixed  dose was very well tol erated in patients with various advanced cancers. Refer to the 
IB for more detailed information on clinical studies of IBI308.  
 The CIBI308B201 Phase 2 study showed robust  PD-1 receptor occupancy (RO) on 
peripheral blood CD3  + T cells by IBI308 was achieve d in patients with 
recurrence/refractory Hodgkin's lymphoma treated with a 200 mg fixed  dose. The overall 
response rate (ORR) per independent radiology review committee ( IRRC) was 65.0% 
(N=60) following treatment with IBI308 at 200mg Q3W . 
 Pharmacokinetics of IBI308 were characterized in  solid cancer patients with an 
elimination half -life (geometric mean) of 14.4 days (ranged from 8.0 -23.3 days) at the 1st  
cycle and 13.4  days (ranged from 10.6 -14.7 days) at the 4 th cycle (steady state).  
 The proposed dose an d dosing intervals are also based on the approved anti -PD-1/PD -L1 
products. Based on literature reports and data obtained from other anti -PD-1 products, 
body size and race are less likely to affect PK or efficacy/safety of anti -PD-1 products at 
the therape utic dose.  
We therefore propose a fixed  dose of 200 mg IBI308 for every 3 weeks (Q3W) in the US trial.  
 
3.3 Randomization Procedures  
Randomization and blinding procedures are not applicable in this open -label study. Eligible 
subjects will be registered and assigned to the available treatment cohorts. Subjects will be 
assigned to the cohort allocation after they have given their written informed consent and have 
completed the necessary baseline assessments. The subject will be assigned an identification 
numbe r, which will be used on all case report forms (CRFs) and other study -related 
documentation  
 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 25 
 4. STUDY POPULATION  
4.1 Patient Number/Study Sites  
Approximately 50 subjects will be recruited for this study in the United States.  
 
4.2 Eligibility Criteria  
4.2.1  Overview  
Patie nts must have baseline evaluations performed prior to the first dose of study drug and must 
meet all inclusion and exclusion criteria.  In addition, the patient must be thoroughly informed 
about all aspects of the study, including the study visit schedule and required evaluations and 
all regulatory requirements for informed consent.  The written informed consent must be 
obtained from the patient prior to enrollment.   
The following criteria apply to all patients enrolled in the study unless otherwise specif ied. 
 
4.2.2 Inclusion Criteria  
 
1) Subjects able to give voluntary informed consent, understand the study and are willing 
to follow and complete all the test procedures.   
2) Subjects (males and females) of childbearing potential should be willing to use reliable  
contraception method s that are deemed effective by the investigator from visit 1 through  90 
days following the last dose of study drug. Postmenopausal women must have been amenorrhea  
for at least 12 months to be considered of non -childbearing potential.  
3) Male or female subjects ≥18 years  
a) At least one measurable lesion (per RECIST version 1.1)  
b) Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1.  
c) Subjects with life expectancy of ≥ 3 month  
4) If subject received anti -tumor therapy:  
a) Generalized radiation therapy must have been completed 3 weeks prior  to enrollment , 
or local radiotherapy or radiation therapy for bone metastases for 2 weeks prior to 
enrollment. Treatment with  radiopharmaceuticals must have been completed  8 weeks 
prior to enrollment.  
b) Previous chemotherapy, biotherapy (tumor vaccines, cytokines, or growth factors that 
control cancer), tyrosine kinase inhibitors, or approved targeting and other treatments 
should have completed  at least 3 weeks prior to the f irst administered dose in  this study;  
5) Subjects must have adequate organ function (liver, kidney function and hematopoietic 
function tests) prior IBI308 administration  
a) Absolute neutrophil count (ANC) ≥ 1.5 x109/L 
b) Platelet count  ≥ 100 x 109/L 
c) Hemoglobin ≥ 9 g / dL  (whole blood or component transfusion within 7 days before 1st 
dose of study drug is prohibited)  
d) Renal function tests: serum creatinine ≤1.5 ×upper limit of normal range (ULN) or an 
estimated glomerular filtration rate (eGFR) ≥ 50 mL/ min/1.73 m2  
e) Liver function tests alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) ≤3 x ULN, for patients with known liver cancer or liver metastases, AST and 
ALT ≤ 5 x ULN  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 26 
 f) Total bilirubin (TBil) ≤1.5 x ULN; If Gilbert's Syndrome may ha ve Bilirubin> 1.5 x 
ULN  
g) Coagulation tests: aPTT ≤ 1.5 x ULN  and INR ≤2 .0 
6) Cohort Specific Inclusion Criteria:  
Cohort 1: Advanced/metastatic cancers with high TMB expression  
 
i. Advanced/metastatic cancers with TMB level > 10 mut/ Mb 
ii. Histologically or cytologically confirmed unresectable Stage III/IV NSCLC or other 
advanced/metastatic cancers  (for example, melanoma, bladder cancer, SCLC, prostate 
cancer, colorectal cancer, gastric cancer)   
iii. Separate informed consent is required for subjects who provide fresh biopsies for serial 
tumor biopsies for biomarker testing .  TMB testing should be performed on the most 
recently obtained tumor sample . 
iv. Subjects must be tested for TMB level before entering the study, and pre -screen 
informed consent is required for TM B testing. Subjects who have existing 
FoundationOne TMB testing results from within 6 months of study entry do not need 
to have repeat testing.  
v. Refractory or intolerant to standard therapy or for whom no standard therapy exists.  
Subjects must have no avai lable therapy likely to confer clinical benefit for their cancer.  
Subjects who experienced irAE grade ≥ 3, or grade 2 recurrent pneumonitis , or who 
had to discontinue prior anti -PD-1/PD -L1 treatment due to irAEs of any grade will not 
be eligible.  
vi. NSCLC subjects with EGFR mutation and/or ALK rearrangement and/or ROS -1 
positive, should have received appropriate targeted therapy and are refractory to 
targeted therapy prior to enrolling this trial.   
 
Cohort 2: Advanced/metastatic endometrial Cancer  
i. Histologically confirmed advanced/metastatic endometrial cancer .  
ii. Refractory or intolerant to standard therapy,  and no available therapy likely to confer 
clinical benefit for their cancer . Subjects who experienced irAE grade ≥ 3, or who had to 
discontinue prior anti -PD-1/PD -L1 treatment due to irAEs of any grade will not be eligible.   
 
4.2.3 Exclusion Criteria  
1) Legal incapacity or limited legal capacity.  
2) Pregnancy, lactation, breastfeeding.  
3) Concurrent anticancer treatment (e.g., cyto reductive therapy or cytokine therapy except for 
erythropoietin) or use of other investigational product within 28 days before start of trial 
treatment; major surgery within 28 days before start of trial treatment (excluding prior 
diagnostic biopsy.  
Note:  Small molecule or antibody targeted therapy <  3 weeks from start of trial treatment  
will be excluded . 
4) Received a biologic (G -CSF, GM -CSF) within 14 days prior to the first dose of study drug.  
5) Vaccination within 4 weeks of first dose of IBI308 and while on  study except for 
administration of inactivated vaccines (e.g., inactivated influenza vaccines)  
6) Failure to recover from adverse events from the most recent  anti-tumor treatment to 
CTCAE ≤ grade 1 or baseline with the  exception of alopecia;  
7) Active autoimmune disease requiring systemic treatment within the past 1 year or a 
documented history of clinically severe autoimmune disease or a syndrome that requires 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 27 
 systemic steroids or immunosuppressive agents during the conduct of this study. 
Except ions: - Vitiligo, eczema, psoriasis (<10% of body surface area (BSA) of skin 
eruption or systemic involvement) or resolved childhood asthma/atopy , autoimmune 
hypothyroidism stable on hormone replacement.  
8) History of idiopathic pulmonary fibrosis, pneumonit is (including drug induced), organizing 
pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or 
evidence of active pneumonitis on screening chest computed tomography (CT) scan. 
History of radiation pneumonitis in the radiatio n field (fibrosis) is permitted.  
9) Acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.  
10) History of primary immunodeficiency, stem cell or organ transplant, or previous clinical 
diagnosis of tuberculosis.  
11) Subject who hav e had severe infection within 4 weeks or signs and symptoms of any active 
infection within 2 weeks prior to the first dose administration.  
12) Known allergies, hypersensitivity, or intolerance to protein -based therapies or with a 
history of any significant dru g allergy (e.g., anaphylaxis, hepatotoxicity, immune -mediated 
thrombocytopenia or anemia  
13) Subjects  who experienced (irAE) grade ≥3 immunotherapy -related adverse events . 
Subjects with CNS metastasis unless they are asymptomatic or adequately treated with 
radiotherapy and/or surgery and subjects are neurologically stable with minimal residual 
symptoms/signs 14 days prior to dosing.  
14) Patients who require high dose of systemic corticosteroids (>10 mg/day prednisone or 
equivalents) for at least 2 weeks prior to tr eatment are not eligible.  
15) Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure (New 
York Heart Association) NYHA III or IV, unstable angina pectoris even if medically 
controlled, history of myocardial infarction during the l ast 3 months, serious arrhythmias 
requiring medication (with exception of atrial fibrillation or paroxysmal supraventricular 
tachycardia).  
16) Any other serious underlying medical (e.g., uncontrolled hypertension,  active uncontrolled 
infection, active gastric  ulcer, uncontrolled seizures, cerebrovascular incidents, 
gastrointestinal bleeding, severe signs and symptoms of coagulation and clotting disorders, 
other serious cardiac conditions not listed in exclusion criteria), psychiatric, psychological, 
familial o r geographical condition that, in the judgment of the investigator, may interfere 
with the planned staging, treatment and follow -up, affect patient compliance or place the 
patient at high risk from treatment -related complications.  
 
4.3 Subject Screening  Proced ures 
A written ICF must be obtained prior to initiating pre -screening for TMB status with the 
FoundationOne assay. TMB testing should be performed on the most recently obtained tumor 
sample. Specimen handling is described in the Biomarker section of this p rotocol (6.1.3.2).  If 
the subject meets the TMB eligibility criteria for cohort 1, the subject will be asked to sign the 
main study ICF and will then undergo the complete screening.  Subjects who have existing 
FoundationOne TMB testing results from within  6 months of study entry do not need to have 
repeat testing.  
Written ICF must be obtained prior to any study -related procedures. Screening procedures will 
be conducted at qualified clinical research centers. Demographic data to be recorded in the 
eCRFs  include subjects’ gender, race, and date of birth.   
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 28 
 Prior to participation in the study, all volunteers will have a routine history and physical along 
with screening blood tests . The screening procedures and assessments must be completed 
within 28 days of  the study treatment visit Day 1 (Schedule of Events ).  Weight, height and 
vital signs  will also be obtained upon screening. All female volunteers will have a urine 
pregnancy test and will be asked to participate only if  the test is negative.  In addition, female 
and male subjects will be asked to practice a reliable medically accepted form of birth control 
during participation in the study.  In this proposed application, all subjec ts will have a baseline  
12-lead ECG to exclude cardiovascular disease before entering the study.  Subject’s current 
medication schedule will be reviewed to ensure patients safety during the treatment.   
After all the screening results are obtained eligibility criteria will be reviewed and a compl ete 
clinical evaluation will be performed. All screening assessments will occur within 28 days prior 
to the first dose of study drug.  
If an assessment was performed as part of the subject’s routine clinical evaluation and not 
specifically for this study, it does not need to be repeated after signed ICF has been obtained. 
However, the assessments must fulfill the study requirements and should be performed within 
the specified timeframe prior to the first dose of study drug. Retesting of abnormal screening 
values that lead to exclusion are allowed only once during the Screening Phase (to reassess 
eligibility). The last result obtained prior to the first dose of study drug will be used to determine 
eligibility.  
The prospective subject’s medical history will b e assessed prior to the initial treatment for 
continued study eligibility and adherence to final inclusion/exclusion criteria. During the 
Treatment Period, a symptom -based assessment will be maintained. The recent medical history 
assessment will include re cent medication changes that have occurred since the previous visit.  
5. STUDY INTERVENTION  
5.1 Study Drug  
The IBI308 drug product (DP), is a 10 mg/mL solution for IV infusion, to be stored at 2 -8 ℃, 
in single -use colorless and transparent 15  ml borosilicate glas s Type I vials.  Each vial of 
IBI308 DP contains 100 mg/10 mL of IBI308 drug substance in 30.06 mg/mL mannitol, 3.73 
mg/mL L -histidine, 2.92 mg/mL sodium chloride, 0.0075 mg/mL ethylenediaminetetraacetic 
acid (EDTA -2Na), 0.2 mg/mL polysorbate 80, 5.88 mg/m L sodium citrate dehydrate.   The DP 
vial is capped with polytetrafluoroethylene membrane chlorinated butyl rubber stopper and 
sealed with an aluminum cap.  IBI308 will be supplied by the sponsor.  
The storage and handling of the diluted DP should meet the  following time and temperature 
limits:  
 Storage time should be limited to 8 hours at room temperature following DP dilution into 
the infusion bag  including infusion time.  
 Storage time should be limited to 24 hours at 2-8 oC following DP dilution into the i nfusion 
bag including infusion time.  
5.2 Treatment Compliance and drug accountability  
The site should maintain accurate dosage preparation records and should ensure that all 
pertinent/required information on the preparation and administration of the dose is c aptured in 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 29 
 source documents, and appropriate dosing information is entered onto CRFs. This information 
should be readily available during the monitoring visits.  
Upon termination of the study, or at the request of the sponsor, the pharmacist must return the 
study drugs to sponsor, unless it is destroyed at the site as agreed upon by both the sponsor and 
the site.  
 
5.3 Dosage and Drug Administration  
This is an open labe l study  without  blinding or randomization.  Prior to use,  DP is supplied as 
a solution for IV infusion packaged in single -use glass vials. Prior to administration,  IBI308 
will be diluted to the required volume to achieve a final concentration of  2mg/mL using 0.9% 
sodium chloride solution. Administer the infusion over 60 minutes through an intravenous line 
containing a sterile, nonpyrogenic, low protein binding in -line filter (pore size of 0.2 
micrometer to 1.2 micrometer).   
All dose administrations will  be performed in the clinical center under the supervision of 
appropriately trained staff. Blood samples will not be collected from the arm used for the IV 
infusion for at least 24 hours after administration.  Subjects should not receive prophylactic pre -
medication, unless they have suffered an infusion reaction in a prior cycle of administration of 
study drug.  
 
5.4 Dosing Procedure and Treatment cycles  
This trial will include  2 cohorts, and total of approximately 50 subjects. Please see Table -5. 
Each cycle will consist of 21 days and each subject will receive IBI308 on a Day1 of each 
cycle and continue treatment with IBI308 until disease progression or intolerable toxicity, 
withdraw al of consent, or end of study, whichever occurs first.  
 
Table -5. Study population, sample size and treatment dose.  
Cohort Number  Indication  Patient Number  IBI308 Dose  
Cohort 1  Advanced/metastatic cancers with TMB 
level >10mut/Mb  2 enrolled as of 
1/7/2019  200 mg  
Cohort 2  Advanced/Metastatic Endometrial Cancer  40 200 mg  
 
5.5 Duration of Treatment  
Patients may continue to receive IBI308 until disease progression or intolerable toxicity, death, 
withdrawal of consent, or end of study up  to 2 years, whichever occurs first .  
 
5.6 Treatment Beyond Disease Progression  
Subjects treated with IBI308  will be permitted to continue treatment beyond initial RECIST 
1.1 defined disease progression as long as they meet the following criteria:  
1. Investigator -assessed clinical benefit, and do not have rapid disease progression  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 30 
 2. Continue to meet all other study protocol eligibility criteria  
3. Tolerance of study drug  
4. Stable performance status  
5. Treatment beyond progression will not delay  an imminent intervention to prevent serious 
complications of disease progression (e .g. CNS metastases)  
6. Subject provides written informed consent prior to receiving additional IBI308  treatment, 
using an ICF describing any reasonably foreseeable risks o r discomforts, or other alternative 
treatment options.  
 
The decision to continue treatment beyond initial progression should be discussed with the 
Sponsor Medical Manager  and documented in the study records.  
A radiographic assessment/scan should be perfor med within six (6) weeks of original disease 
progression to determine whether there has been a decrease in the tumor size, or continued 
disease progression . The assessment of clinical benefit should be assessed  by clinical judgment 
as to whether the subjec t is clinically deteriorating and unlikely to receive any benefit from 
continued treatment with IBI308.  
If the investigator considers that  the subject on IBI308 continues to achieve clinical benefit by 
continuing treatment, the subject should remain on the trial and continue to receive monitoring 
according to the Schedule of  Events . The decision to continue treatment should be d iscussed 
with the Sponsor Medical Manager  and documented in the study records.  
 
5.7 Dose Modification and Management of Withholding, Resuming or Discontinuation of 
the Study Drug  
Dose modifications are not permitted during this study unless intolerable  toxici ties occur.  If 
significant toxicity occurs, dosing may be delayed or permanently discontinued as described 
below. In the event of multiple toxicities, dosing management should be based on the worst 
toxicity observed (Refer to Section  5.8). 
 
5.7.1 Criteria for Withholding Study Drug  
1) Grade ≥2 non -skin, drug -related AEs with the following exceptions:  Grade 2 drug -related 
fatigue or laboratory abnormalities do not require a treatment delay  
2) Grade ≥2 immune -mediated ocular disease will result in withholding study drug . 
3) Any Grade 3 drug -related laboratory abnormalities with the following exceptions for 
lymphopenia, leukopenia, AST, ALT or total bilirubin  
a. Grade 3 lymphopenia or leukopenia does not require dose delay  
b. If a subject’s  baseline AST, ALT or total bilirubin was WNL, delay dosing for drug -
related Grade ≥2 toxicity  
c. If a subject’s  baseline AST, ALT or total bilirubin was in a Grade 1 toxicity range, 
delay dosing for drug -related Grade ≥3 toxicity  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 31 
 4) Any AE, laboratory abnormali ties, or intercurrent illness, which in the judgment of the 
Investigator warrants delaying the dose of study drug.   
 
5.7.2 Criteria to Resume Treatment  
Subjects may resume treatment with study drug(s) when the drug -related AEs resolve to Grade 
≤1 or baseline val ue or with the following:  
1) Patients with Grade 2 fatigue  
2) Patients with Grade 2 skin toxicity provided they  have not experienced Grade 3 or 
higher  skin toxicity  
3) Drug -related pulmonary toxicity, diarrhea or colitis must have resolved to baseline 
before treatment is resumed  
4) Drug -related endocrinopathies adequately controlled with only physiologic hormone 
replacement may resume treatment  
 
5.7.3 Criteria for Drug Discontinuation  
1) Discontinue treatment for Grade 3 or higher drug -related AEs of pneumonitis, creatin ine, 
neuropathy, diarrhea/colitis that may lead to bowel perforation  
2) Discontinue treatment for any other Grade 4 drug -related AEs or laboratory abnormality, 
except for the following events which do not require discontinuation.  
a. Isolated grade 4 amylase or l ipase abnormalities that are not associated with symptoms 
or clinical manifestations of pancreatitis and decrease to < grade 4 within 1 week of 
onset  
b. Isolated grade 4 electrolyte imbalances/abnormalities that are not associated with 
clinical sequelae and are corrected with supplementation/appropriate management 
within 72 hours of their onset  
3) Discontinue treatment for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks (except for endocrinopathies tha t are 
controlled with replacement hormones)  
4) Grade 4 increases in liver function tests (subjects with liver involvement) or Grade 3 
increases in liver function tests (subjects without liver involvement)  
5) Discontinue treatment for persistent drug -related AE that do es not recover to Grade 0 -1 or 
baseline within 12 weeks unless otherwise agreed to by the sponsor representative and the 
investigator based on evidence of clinical benefit  
6) Discontinue treatment for any recurrent Grade 2 pneumonitis or recurrence of same Grade 
3 AEs  
7) Discontinue treatment for any AE, laboratory abnormality, or intercurrent illness which, in 
the judgment of the investigator, presents a substantial clinical risk to the subject with 
continued investigational drug dosing.  
Following treatm ent discontinuation, the subject should complete the EOT Visit as described 
in Schedule  of Events .  
 
5.8 Special Precautions and Clinical Interventions  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 32 
 5.8.1 Infusion Reactions  
All therapeutic monoclonal antibodies (mAbs) used for  cancer treatment have the potential to 
cause infusion reactions.  Symptoms vary with a wide spectrum of severity, ranging from mild 
fever and chills to life -threatening anaphylaxis with bronchospasm, and hypotension. Typically, 
infusion reactions to monoc lonal antibodies develop within 30 -120 minutes after the initiation 
of drug infusion, although symptoms may not show up until 24 hours. The majority of reactions 
occur after the first or second exposure to drug, although it can also rarely occur during 
subsequent treatments. Additionally, the risk of infusion reaction declines with each 
subsequent course of therapy.  
Most common symptoms or “standard infusion reactions” (SIRs) are fever/chills, nausea, 
vomiting diarrhea, itching/flushing, rash changes in blood pressure ( BP) and heart rate ( HR), 
dyspnea, chest discomfort , back and abdominal pain.   
Although exact mechanism of SIRs caused by mAbs is not fully clear, most likely it is a result 
of antibody -antigen interactions resulting in cytokine release.  
Although premedication can help to prevent and/or reduce the severity of infusion reactions, 
anaphylaxis generally cannot be prevented by premedication. Thus, the following supplies and 
equipment needs to be readily  available  in any area where chemotherapy  is administered: IV 
fluids, epinephrine, antihistamines, oxygen, aerosolized bronchodilators, intubation and 
tracheostomy equipment, and a defibrillator.  
The investigator will be responsible for managing infusion related and hypersensitivity 
reactions acc ording to local standard procedure or follow the recommendations listed Table -6. 
Table -6 Management of Infusion -Related Reacti ons/Hypersensitivity Reactions (NCI 
CTCAE Grade)  
Grade 1  
Mild transient reaction; 
infusion interruption NOT 
indicated; intervention 
NOT indicated   Monitor subject closely until recovery from symptoms, Consider 
premedication with 50 mg diphenhydramine or 650  acetaminophen at least 
30 minutes before additional study drug administration  
Grade 2  
Cessation of infusion or 
therapy is indicated. 
Responds promptly to 
symptomatic treatment.   Stop infusion ; start IV saline infusion; IV 50 mg diphenhydramine or 650 
acetaminophen ; depending on symptoms, consider corticosteroids and 
bronchodilator therapy; remain at bedside and monitor subject until 
recovery from symptoms  
 Restart infusion at 50% of initial rate: if no further complications ensue after 
30 minutes, the rate may be increased to 100% of the original infusion rate; 
monitor subject closely.   
 Prophylactic medication indicated for less than or equal to 24 hours  
 Symptoms recur: stop and discontinue further treatment at that visit; 
administer diphenhydramine 50 mg IV , and remain at bedside and monitor 
the subject until resolution of symptoms. The amount of study drug infused 
must be recorded on the eCRF.  
Grade 3 -4  
Prolonged recurrence of 
symptoms, hospitalization 
indicated for other clinical 
sequelae, maybe life 
threatening and  Stop infusion ; start IV saline infusion; recommend bronchodilators, 
epinephrine 0.2 to 1 mg of a 1: 1,000 solution for subcutaneous 
administration or 0.1 to 0.25 mg of a 1: 10,000 solution injected slowly for 
IV administration, and/or diphenhydramine 50 mg IV with 
methylprednisolone 100 mg IV (or equivalent), as needed.  
 Subject should be monitored until the investigator is comfortable that the 
symptoms will not recur. Investi gators should follow their institutional 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 33 
 hospitalization may 
require.  
Should discontinuation 
from treatment  guidelines for the treatment of anaphylaxis. In the case of late -occurring 
hypersensitivity symptoms (for example, appearance of a localized or 
generalized pruritus within 1 week after treatment), symptomatic treatm ent 
may be given (e.g., oral antihistamine, or corticosteroids).  
 
5.8.2 Extravasation  
In the event of extravasation, infusion should be stopped immediately and the investigator 
needs to be consulted immediately. Treatment of extravasation should follow local st andard of 
care.  
 
5.8.3 Immune Related Adverse Events (irAE)  
Checkpoint inhibition is associated with a wide spectrum of side effects defined as immune -
related adverse events (irAE). IrAEs may include gastrointestinal, hepatic, endocrine, 
dermatologic and inflamm atory events. Early recognition and management of these irAEs may 
mitigate more severe and subsequent toxicities.  
General, treatment is based upon the severity of the observed toxicity. Recommendations for 
irAE treatment:  
 Subjects should be evaluated to identify any alternative etiology.  
 In the absence of a clear alternative etiology, all events of an inflammatory nature should 
be considered immune related.  
 Symptomatic and/or topical therapy should be considered for low -grade events.  
 Systemic corticosteroids should be considered for a persistent low -grade event or for a 
severe event.  
Immunosuppressive agents should be considered for events not responding to systemic 
corticosteroids.  
 
5.8.3.1  Management of Gastrointestinal irAEs  
Diarrhea/colitis is the  most common GI symptom in patients treated with checkpoint inhibitors.  
Usually it presents approximately in six weeks after starting treatment.  
The investigator will be responsible for managing GI irAEs according to local standard 
procedure or follow the  recommendations listed Table -7. 
 
Table -7  Management of Gastrointestinal irAEs  
Grade 1   Symptomatic treatment (for example, loperamide) 
according to institutional standards;  
 Close monitoring; instruct subject to report 
worsening immediately and treat as Grade 2 
Grade 2   5 days: Symptomatic treatment according to 
institutional standards  
 >5 days or recurrence: 0.5–1.0 mg/kg/d 
methylprednisolone; consider prophylactic antibiotics;  
 Persistence or worsening despite steroids >3 days: treat 
as Grade 3/4  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 34 
  Improvement to Grade 1: taper steroids over at least 4 
weeks, consider prophylactic antibiotics for 
opportunistic infections, resu me study therapy per 
protocol  
Grade 3 -4  
permanent discontinuation from treatment   Immediately: 1.0–2.0 mg/kg/d methylprednisolone IV; 
consider prophylactic antibiotics and lower colonoscopy  
 Persistence >3 days or recurrence: add infliximab 5 
mg/kg (if no  contraindication such as perforation or 
sepsis)  
 Improvement to Grade 2 within 3 days: taper steroids 
over at least 4 weeks  
 
5.8.3.2  Management of Hepatic irAEs  
The investigator will be responsible for managing hepatic irAEs according to local standard 
procedur e or follow the recommendations listed Table -8:  
Hepatic function test (transaminases and bilirubin) should be monitored prior each 
administration of the investigational drug.  
 
Table -8  Management of Hepatic irAEs  
Grade 1   Continue liver function monitoring  
 If worsens: Treat as Grade 2  
Grade 2   Monitor every 3 days;  
 Returning to baseline: resume per protocol monitoring  
 Patients who experience grade 2 hepatitis regardless of 
duration should receive  0.5-1.0 mg/kg/d ay 
methylprednisolone IV or oral equivalent; consider 
prophylactic antibiotics  
 LFT return to Grade 1 or baseline: taper steroids over at least 
4 weeks; resume routine monitoring and resume study 
treatment per protocol  
Grade 3 -4 Should be discontin ued  Monitor every 2 days;  
 Immediately: 1.0-2.0 mg/kg/d methylprednisolone IV or IV 
equivalent; start prophylactic antibiotics; consult 
gastroenterologist  
 Persistence >3 days or recurrence: add mycophenolate 
mofetil 1g bid; if no response within 5 days, c onsider other 
immunosuppressants per local guidelines  
 LFT return to Grade 2: stop immunosuppressants  
 LFT return to Grade 1: taper steroids over at least 4 weeks  
 
5.8.3.3  Management of Dermatological irAEs.  
The investigator will be responsible for managing dermatologic irAEs according to local 
standard procedure or follow the recommendations listed Table -9. For guideline of dose 
delay/discontinuation, refer to Section 5.7.  
Anti-PD-1 antibodies can cause immune mediated rash, including Steven -Johnson Syndrome 
(SJS) and toxic epidermal necrolysis (TEN) that can also lead to fatal  outcomes in some cases.  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 35 
 If SJS and TEN symptoms are suspected withhold IBI308 and refer to specialized care; if SJS 
and TEN confirmed permanently discontinue IBI308.  
 
Table -9 Management of Dermatological irAEs.  
Grade 1 -2  Symptomatic treatment (for example, antihistamines, topical steroids);  
 Persistence ≤2 weeks or recurrence: consider skin biopsy; consider 0.5 -1.0 
mg/kg/d methylprednisolone IV or oral equivalent; consider prophylactic 
antibiotics  
 Improvement to ≤Grade 1: taper steroids over at least 4 weeks  
 Worsening to >Grade 2: treat as Grade 3 -4 
Grade 3 -4 Should 
discontinuation 
from treatment be 
warranted   Consult dermatologist; consider skin biopsy; start 1.0 -2.0 mg/kg/d 
methylprednisolone IV or IV equivalent; add prop hylactic antibiotics  
 Improvement to ≤ Grade 1: taper steroids over at least 4 weeks  
 
5.8.3.4  Management of Endocrine irAEs  
Endocrinopathies  associated with checkpoint inhibitors include disorders of pituitary, thyroid, 
or adrenal glands, which often represents as with nonspecific symptoms such as nausea, 
headache, fatigue, and vision change.  
Hypophysitis is often manifested by headaches and fatigue. It is diagnosed by reduced levels 
of pituitary hormones (TSH, follicle -stimulating hormone (FSH), luteinizing hormone (LH), 
growth hormone (GH), Adrenocorticotropic hormone (ACTH ), and prolactin). In the event 
when hypohysitis is suspect investiga tional drug should be discontinued and high dose steroids 
need to be started to prevent the need for longer -term hormone replacement. In case of 
endocrine AEs endocrinology consults is recommended.  
Hormone replacement needs be started as clinically indicat ed and corticosteroids should be 
administered at a dose of 1 mg/kg/day prednisone equivalents followed by corticosteroid taper 
for moderate (Grade 2) or greater hypophysitis.  
Permanently discontinue IBI208 if AE is ≥ Grade 3. Endocrinology consults is reco mmended.  
In case of suspicion of adrenal crisis (e.g. severe dehydration, hypotension, shock out of 
proportion to current illness) discontinue IBI308, rule out sepsis, and urgently initiate IV fluids, 
high dose of IV steroids with mineralocorticoid activit y and consult endocrinologist.  
Administer corticosteroids at a dose of 1 to 2 mg/kg/day prednisone equivalents followed by a 
corticosteroid taper for severe (Grade 3) or life -threatening (Grade 4) adrenal insufficiency.  
In addition to endocrine consult, w hen hypophysitis and adrenal insufficiency AE occur 
≥Grade 2 withhold the dose until improves to grade 0 or 1 and permanently discontinue  
if≥Grade 3.  
In the event of autoimmune hyper - or hypothyroidism thyroid functions needs to be monitored 
and hormone -replacement administered in case of hypothyroidism. No recommended dose 
adjustments are indicated during thyroid AEs.  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 36 
  
5.8.3.5  Management of Pulmonary irAEs  
Prior diagnosing drug -induced pneumonitis, alternative diagnoses, including infections needs 
to be excluded.  Although pneumonitis is not a common complication, it is a potentially severe 
or fatal complication with checkpoint inhibitor immunotherapy treatment.  
The investigator will be responsible for managing pulmonary irAEs according to local standard 
procedure or follow the recommendations listed Table -10. 
 
Table -10  Management of Pulmonary irAEs.  
Grade 1  
Asymptomatic; clinical or diagnostic 
observations only; intervention not 
indicated   Withhold Investigational Drug for 2 -4 weeks with 
close monitoring.  
 Monitor for symptoms every 2 -3 days; consider 
pulmonary and infectious -disease consult; Re -image 
every 3 weeks.  
Grade 2  
Symptomatic; medical intervention 
indicated   Withhold Investigational Drug   
 Monitor symptoms daily; Consult to pulmonary and 
infectious -disease; consider bronchoscopy and lung 
biopsy; consider hospitalization  
 Immediately: start IV steroids or oral equivalent; 
prophylactic antibiotics   
 Additional immunosuppression may be used in patients 
with worsening of pneumonitis  
 Persistence for 2 weeks or worsening: treat as Grade 3 -4 
 Improvement to ≤ Grade 1 or baseline: taper steroids 
over at least 4 weeks  
Grade 3 -4 
Severe symptoms; limiting self -care ADL; 
oxygen indicated  
Discontinuation permanently   Hospitalize; pulmonary and infectious -disease consult; 
consider bronchoscopy and lung biopsy  
Immediately: 2-4 mg/kg/d methylprednisolone or IV 
equivalent; add prophylactic antibiotics;  
Persistence for 2 days or worsening: add immunosuppression 
(e.g., infliximab, cyclophosphamide, IVIG, or mycophenolate 
mofetil)  
Improvement to ≤ Grade 2: taper steroids over at least 6 weeks  
 
5.8.3.6  Management of Renal irAEs  
Immune -mediated nephritis and renal dysfunction is less commonly caused by PD -1/PD -L1 
inhibitors. Patients need to be monitored periodically for elevated serum creatinine prior to and 
during treatment.  
The investigator will be responsible for managing ren al irAEs according to local standard 
procedure or follow the recommendations listed Table -11. 
 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 37 
 Table -11 Management of Renal irAEs.  
Grade 1  Monitor creatinine weekly  
 Creatinine returns to baseline: continue monitoring per protocol  
 Creatinine increases: treat as Grade ≥2  
Grade 2 -3 
Permanently discontinue 
from treatment for 
Grade 3 nephritis 
regardless of duration  Withhold investigational Drug  
 Monitor creatinine every ≤3 days  
 Immediately: 1-2 mg/kg/d prednisone or equivalent; consider prophylactic 
antibiotics and nephrology consult if no i mprovement to ≤Grade 1: taper 
steroids over at least 4 weeks . 
 Grade 3 nephritis regardl ess of duration will be permanently discontinued.  
 Persistence >7 days or worsening: treat as Grade 4  
Grade 4  
Permanently discontinue 
from treatment  
regardless of duration  Monitor creatinine daily  
 Immediately: consult nephrologist; consider renal biopsy; start 1.0 -2.0 
mg/kg/d methylprednisolone IV or IV equivalent; add prophylactic 
antibiotics  
 Improvement to ≤Grade 1: taper steroids over at least 4 weeks  
 
5.8.3.7  Management of Pancreatic irAEs  
Although elevated levels of serum amylase and lipase have been reported with check point 
inhibitors but often these laboratory findings do not fulfill the criteria for acute pancreatitis and 
most of these patients are asymptomatic. Withhold treatment if Grade 2 or 3 pancreatitis, or 
Grade 3 or 4 increases in amylase o r lipase levels occurs (>2.0 times ULN). In asymptomatic 
patients close observation is recommended. PI should ensure that subjects do not exhibit 
pancreatitis associated symptoms, such as abdominal pain. Corticosteroid treatment is not 
indicated in asympto matic patients with moderate pancreatic enzyme elevations, if no other 
signs or symptoms of pancreatic inflammation exists. In any case of recurrent pancreatitis or 
grade 3 pancreatitis discontinue treatment permanently.  
 
5.8.3.8  Management of Cardiac irAEs  
Cardio toxicity may develop in the absence of cardiac risk factors and may be associated with 
a more general myositis and other irAEs. Treatment for cardiac toxicities is usually high dose 
steroids although in some cases symptoms might still progress despite aggr essive treatment.  
In case of elevated troponin and conductions abnormalities immediate transfer to a coronary 
care unit should be considered.  
 
5.8.3.9  Management of Neurologic irAEs  
A variety of neurologic syndromes have been associated with checkpoint blockade. Commonly 
reported neurologic cases includes but not limited to Guillain -Barre syndrome, myasthenia 
gravis, transverse myelitis , autoimmune encephalitis.  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 38 
 Serious neurologic irAEs should be treated with corticosteroids and consultation with 
neurology is ind icated. Additionally, plasmapheresis and intravenous immunoglobulin 
treatments might be necessary.  
 
5.8.3.10  Other Precautions  
Uveitis, iritis, myositis, hemolytic anemia, seizures, vasculitis, polymyalgia rheumatica, facial   
and   abducens   nerve   paresis were also associated with anti -PD-1 antibodies.  The investigator 
will be responsible for managing irAE according to local standard procedure or refer to 
specialists.  
 
5.9 Concomitant Medication  
Some concomitant medications are allowed during the study to treat infusion -related reactions 
and other adverse events for symptomatic relief or management irAEs as specified in Section 
5.8 above. Hormonal replacement therapy  anticoagulation therapy, oral contraceptives, and 
inhaled corticosteroids/mineralocorticoids can be used or continue their use during the study at 
the discretion of the investigator.   
 
5.10 End of Treatment (EOT)  
An EOT Visit will be scheduled within  7days ±3 days after the last dose of study drug for all 
subjects, including those discontinuing treatment for any reason, except for patients lost to 
follow -up, death, or withdrawal of consent for study participation. The EOT Visit should be 
completed before startin g any subsequent anticancer treatment. If a subject is unable to return 
to the site for the EOT Visit, the subject should be contacted to collect AEs and concomitant 
medications that occur up to 30± 7 days after the last dose of study drug.  
Subjects will be instructed that study drug will not be made available to them after they have 
completed/discontinued study drug and that they should return to their primary physician to 
determine standard of care.  
 
5.11 Follow -up 
For follow -up procedures see Schedule of Events . At least 30 days and no more than 37 days 
after discontinuation of treatment, subjects will return to undergo the assessments outlined in 
the Schedule of Events as well as a review of concomitant medi cations, vital signs, and 
assessment for resolution of any treatment related toxicity. Subjects continuing to experience 
toxicity at this point following discontinuation of treatment will continue to be followed at least 
every 4 weeks until resolution or d etermination, in the clinical judgment of the investigator, 
that no further improvement is expected.  
In the event a subject is unable to return to the clinic for the follow -up visit, telephone contact 
with the subject to assess AEs and concomitant medicat ions and treatment is expected. If 
laboratory assessments are needed to follow -up unresolved AEs, retrieval of assessments 
performed at an institution local to the subject is acceptable.  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 39 
 To collect OS data, subjects will be contacted by telephone every 3 months  (± 7 days) post -
EOT  visit.  
 
5.12 Removal from Study Treatment and off -Study Criteria  
Participation in this research study is completely voluntary. Subjects are free to withdraw from 
this study at any time by informing the investigator.  If a subject, for  whatever reason, no longer 
appropriate to continue receiving study therapy, they will be notified and withdrawn from the 
study.  Furthermore, if the subject is non -compliant (e.g. non -compliant with visits, 
concomitant medications.) they will be withdrawn  from the study and a replacement subject 
may be recruited.  
Additionally, prior to removal from study, effort s must be made to have all subjects complete 
a safety visit approximately 30 days following the last dose of study therapy.  
 
5.12.1  Criteria for removal from study treatment  
If subjects are taken off study treatment, they will be followed until meeting the Off -Study 
criteria in Section 5.12.2. When subjects are off protocol therapy, data will be still collected to 
meet protocol objectives.  
Also, subjects who complete study treatment will be still followed for other study endpoints. 
Below are Criteria for removal from study treatment:  
 Death  
 EOT  
 Progressive disease  
 Participant requests to be withdrawn from active therapy  
 Unacceptable toxicity  
 Investigator discretion  
 Positive pregnancy test  
 
5.12.2  Off-Study Criteria  
Once a subject is taken off study, no further data can be collected.   
 Participant re quests to be withdrawn from study  
 Subject withdrawal from the follow -up period  
 Subject completed all protocol required follow -ups 
 Death  
 Screen failure  
 
5.13 Pregnancy/Contraception/Nursing  
5.13.1  Pregnancy Testing  
All women who are being considered for participation in the study, and who are not surgically 
sterilized or postmenopausal, will be tested for pregnancy within 72 hours before Cycle 1 
dosing  and after the last dose of study drug. If a urine test is positiv e or borderline (unable to 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 40 
 confirm as negative), a serum β -hCG test will be required. Patients must be excluded in the 
event of a positive or borderline test result. The results of the pregnancy test will be recorded.  
 
5.13.2  Contraception  
IBI308 may have adverse  effects on a fetus in utero. Furthermore, it is not known if IBI308 
has transient adverse effects on the composition of sperm. Non -pregnant, non -breast -feeding 
women may be enrolled if they are considered highly unlikely to conceive. Highly unlikely to 
conceive is defined as 1) surgically sterilized, or 2) postmenopausal (a woman who is ≥45 
years of age and has not had menses for greater than 1 year will be considered postmenopausal), 
or 3) amenorrheaic for <1 year without a hysterectomy or oophorectomy an d with a 
documented FSH value in the postmenopausal range, or 4) not heterosexually active for the 
duration of the study, or 5) heterosexually active and willing to use 2 methods of birth control 
(which is also recommended for the female partners of male p atients). The 2 birth control 
methods can be 2 barrier methods or a barrier method plus a hormonal method to prevent 
pregnancy, used throughout the study starting with Visit 1 through 90 days after the last dose 
of study medication. Male patients enrolled in this study must also agree to use an adequate 
method of contraception starting with Visit 1 through 90 days after the last dose of study drug. 
The following are considered adequate barrier methods of contraception: diaphragm, condom 
(by the partner), co pper intrauterine device, sponge, or spermicide. Appropriate hormonal 
contraceptives will include any registered and marketed contraceptive agent that contains an 
estrogen and/or a progestational agent (including oral, subcutaneous, intrauterine, or 
intram uscular agents). Patients should be informed that taking the study medication may 
involve unknown risks to the fetus (unborn baby) if pregnancy were to occur during the study. 
In order to participate in the study they must adhere to the contraception requi rement 
(described above) for the duration of the study. If there is any question that a patient will not 
reliably comply with the requirements for contraception, that patient should not be entered into 
the study.  
 
5.13.3  Use in Pregnancy  
IBI308 may have adverse e ffects on a fetus; therefore, women with a positive pregnancy test 
at screening will not be eligible for enrollment. If a female subject inadvertently becomes 
pregnant while on treatment with IBI308, the subject will immediately be removed from the 
study. The site will contact the patient at least monthly and document the patient’s status until 
the pregnancy has been completed or terminated. The outcome of the pregnancy will be 
reported to the SPONSOR without delay and within 24 hours if the outcome is a se rious 
adverse experience (e.g., death, abortion, congenital anomaly, or other disabling or life -
threatening complication to the mother or newborn). If a male patient’s partner becomes 
pregnant on study the pregnancy must be reported to the SPONSOR. The stu dy investigator 
will make every effort to obtain permission to follow the outcome of the pregnancy and report 
the condition of the fetus or newborn to the SPONSOR.  See Section 9.6 for the details of 
pregnancy reporting.  
 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 41 
 5.13.4  Use in Nursing Women  
It is unknown whether IBI308 is excreted in human milk. Since many drugs are excreted in 
human milk, and because of the potential for serious adverse reactions in the nursing infant, 
patients who are breast -feeding are not eligible for enrollment.  
 
6. STUDY ASSESSMENT AND  EVALUATIONS  
6.1 Specimen Collection and Evaluations  
6.1.1 Pharmacokinetics (P K) 
Intensive PK blood samples will be drawn from  first 6 subjects  in cohort  1 and first 12 subjects 
in cohort  2, PPK will be drawn from other subjects  at the time points indicated in Table -2. 
Blood samples should be drawn from a site other than the infusion site on days of infusion. If 
the infusion is interrupted, the reason for interruption will also be documented on the CRF. 
Blood samples will be processed to collect serum and stored preferably at -70oC. Serum 
samples will be analyzed for IBI308  by a validated method. For each time point, 2 ml whole 
blood sample needs to be collected for PK testing. Further details on PK sample collection and 
processing will be provided to the site in a procedure manual.  
 
6.1.2 Immunogenicity  
Blood samples for anti -drug antibody (ADA) analyses will be collected at predose  in Cycle 1 
and Cycle 2 and then in every other subsequent cycle, and at the mandatory Safety Follow -up 
Visit or until start of a new anti -cancer therapy, whichever occurs first. Analysis will be 
performed by a central laboratory.  For each time point, 4 ml whole blood sample needs to be 
collected , further details on ADA  sample collection and processing will be provided to the site 
in a procedure manual.  
 
6.1.3 Biomarkers  
A variety of factors that could potentially predict clinical response to IBI308  will be 
investigated in tumor specimens obtained at screening, and in peripheral blood taken both at 
screening (prior to first dose of study drug) and during the study, from all subjects as outlined 
in Schedule of Event s. Data from these investigations will be evaluated for associations with 
objective response, survival (OS, PFS) .  
 
6.1.3.1  Peripheral Blood  Biomarkers   
Serum will be obtained from all subjects prior to first dose of study drug, and during the study 
at every other  cycle. Biomarkers measured in blood  will focus on blood TMB and Serum -
Soluble Factor s. 
To understand the prevalence of circulating proteins and the impact they may have on the 
clinical activity of IBI308 , the protein concentrations of a panel of cytokines, chemokines, and 
other relevant immunomodulatory, serum -soluble factors will be evaluated  by ELISA, serum 
chemistry , and/or other relevant multiplex -based protein assay methods. Examples of analytes 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 42 
 to be assessed include but are not limited to factors induced by IFN γ signaling (e .g. T cell 
chemoattractants CXCL9; CXCL10), antibodies to tumor -associated antigens, and soluble PD -
L1 (PD -L1), which may play an important role in immune tolerance and disease p rogression.  
For each time point, 10 ml whole blood sample needs to be collected for blood biomarker s 
testing. Further details on blood biomarker  sample collection and processing will be provided 
to the site in a procedure manual.  
 
6.1.3.2  Tissue Biomarkers  
Before entry into study, every subject in cohort 1 must have testing for TMB by FoundationOne  
and the information of TMB level  must be available.  The FoundationOne assay was approved 
by The U.S. Food and Drug administration  on Nov 30, 2017,  and it was validated to det ect 
genetic mutations in 324 genes and two genomic signatures in any solid tumor type. Average 
sequencing depth of coverage was greater than 250x, with >100x at >99% of exons. For TMB, 
the number of somatic mutations detected on NGS (interrogat ing 1.2 Mb of the genome) are 
quantified and that value extrapolated to the whole exome using a validated algorithm. 
Alterations likely or known to be bona fide oncogenic drivers and germline polymorphisms are 
excluded. TMB is measured in mutations per meg abase ( Mb). In this study, only patients with 
TMB levels > 10 mut/Mb  are eligible.  
For FoundationOne testing specimens should follow the established FoundationOne  Specimen 
Instruction documentation provided by Foundation Medicine. In summary the sample should 
either be a formalin -fixed, paraffin -embedded tumor tissue block and 1 original H&E slide, or 
10 unstained 4 -5 micron thick slides with 1 H&E slide. The surfa ce area of the specimen should 
be 5-25 mm2. The tumor content of the specimen should be 20 -30% estimated based on nuclei 
count. Cut formalin -fixed paraffin -embedded slides are stable for this analysis for at least 6 
months.  
Acceptable samples include forma lin-fixed paraffin -embedded specimens, including core -
needle biopsies, ne -needle aspirates, and effusion cytologies. Use standard fixation methods to 
preserve nucleic acid integrity. 10% neutral -buffered formalin for 6 –72 hours is industry 
standard. Do not  use other fixatives (Bouins, B5, AZF, Holland’s). Do not decalcify. When 
decalcifcation is required, EDTA is recommended. Do not use strong acids (e.g., hydrochloric 
acid, sulfuric acid, picric acid).  
For other biomarkers, a  formalin -fixed, paraffin -embed ded tumor tissue block or unstained 
slides (minimum 10 requested) of tumor sample (archival or recent) for biomarker evaluation 
will be obtained prior to subject enrollment . A reference laboratory will receive the samples 
for immunohistochemistry (IHC) -based analyses aimed at determining the abundance of the 
immunoregulatory proteins such as PD -L1. Additional immunohistochemical analys is may be 
completed to determine the abundance of other protein markers associ ated with TILS . The 
abundance of each protein monitored (or combinations of proteins) will be correlated with 
clinical endpoints. FFPET may be evaluated also by fluorescent in -situ hybridization (FISH), 
genetic mutation detection methods, and/or by RT -QPCR as part of additional exploratory 
analyses of  putative biomarkers thought to be associated with response or resistance to 
therapeutics . Such analyses will be completed retrospectively and within the scope of informed 
consent.   
 
 
 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 43 
 Tumor  samples : (meeting any of the following requirements ) 
Sample Type  Sample Collecting  Storage 
Temperature  Transportation  Remarks  
Paraffin -embedded 
tissue  
(FFPE)  10~15 copies for 
surgical biopsy, at 
least 5 copies; >15 
copies for puncture 
biopsy; Paraffin 
block 50mg (bean -
size)  <37℃  Room temperature 
is acceptable  Paraffin unstained 
samples within 6 
months.  
Puncture b iopsy  2 punctures 
recommended or at 
least once. 1 -2mm 
diameter and more 
than 0.5cm length 
for each sample.  With preservation 
solution:<25℃  
Without 
preservation 
solution:< -20℃  With dry ice  Try not to keep in 
formalin  
Fresh tissue  No less than 60mg 
(bean -size)  With preservation 
solution:<25℃  
Without 
preservation 
solution:< -20℃  With dry ice  Please ensure the 
tissue sample is 
completely 
immersed in liquid 
once preservation 
solution was used  
 
6.1.4 Safety Laboratory Evaluations  
Safety labs will be drawn to assess AE s. CBC with differential, blood chemistry, thyroid tests 
(TSH, free T3 and T4),  urine analysis will be obtained prior to each dosing. Coagulation tests 
(INR, aPTT) will be obtained within 7 days  prior to first dosing on Day 1 . 
AEs will be graded according to the CTCAE v4.03. Investigators will report whether an AE is 
potentially immune related (irAE).  
7. DATA COLLECTION AND MANAGEMENT  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the site investigator. The investigator is responsible for ensuring the accuracy, completeness, 
legibility, and timeliness of the data reported.  
Hardcopies of the study visit worksheets will be used as source document workshee ts for 
recording data for each participant enrolled in the study.  Data recorded in the electronic case 
report form (eCRF) derived from source documents should be consistent with the data recorded 
on the source documents. All source documents should be com pleted in a neat, legible manner 
to ensure accurate interpretation of data.   
Clinical data (including adverse events (AEs), concomitant medications, and expected adverse 
reactions data) and clinical laboratory data will be entered into E DC, which is a 21 CFR , Part 
11-compliant data capturing system. The data system includes password protection and internal 
quality checks, such as automatic range checks, to identify data that appear inconsistent, 
incomplete, or inaccurate. Clinical data will be entered dire ctly from the source documents.  
Only individuals who have received training on the EDC are allowed to make eCRF entries, 
corrections, and alterations. Training must be documented and a log of all EDC users and their 
rights within the system be maintained. The data management team will raise queries in the 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 44 
 EDC system to resolve discrepancies. The Investigator must verify that all data entries in the 
eCRFs are accurate and correct.  
Any outstanding entries must be completed immediately upon notice. No blank sections should 
be left on CRF and explanations have  to be recorded for all missing data. All source documents 
should be retained. All essential documents should only contain subje ct coded identifiers and 
no personal identifying information should be transmitted.  
 
7.1 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol, study manuals, or 
ICH GCP requirements. The noncompliance may be either on the part of the participant, the 
investigator, or the study site staff. As a result of deviations, corrective actions are to be 
developed by the site and implemented promptly.  
These practices are consistent with ICH GCP:  
 Compliance with Protocol  
 Quality  Assurance and Quality Control  
 Noncompliance  
It is the responsibility of the site investigator to use continuous vigilance to identify and report 
deviations within 5 working days of identification of the protocol deviation, or within 5 
working days of the  scheduled protocol -required activity.  All deviations must be addressed in 
study source documents and if applicable, in eCRFs and study reports, in coordination with the 
sponsor or their designated CRO.  Protocol deviations must be sent to the reviewing I RB per 
their policies. The site investigator is responsible for knowing and adhering to the requirements 
of the reviewing IRB.  
 
7.2 Publication and Data Sharing  
Both the use of data and the publication policy are detailed within the clinical study agreement.  
Intellectual property rights (and related matters) generated by the Investigator and others 
performing the clinical study will be subject to the terms of a c linical study agreement that will 
be agreed between the Institution and the Sponsor or their designee.   
 
8. HUMAN SUBJECT PROTEC TION AND REGULATORY  
OVERSIGHT  
8.1 Informed Consent Processes and Documentation  
In obtaining and documenting informed consent, the inve stigator must comply with applicable 
regulatory requirements (e.g., 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56) and should 
adhere to ICH GCP. Prior to the beginning of the trial, the investigator should have the IRB’s 
written approval for the protocol and the written ICFs and any other written information to be 
provided to the participants. Participants will be asked to read and review IRB -approved ICFs 
and other written information.  ICF should include detailed description of study procedures, 
risk and  benefits, directions, participant’s rights, compensation if applicable, and contact of 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 45 
 Human Subject Protection Services.  Additionally, investigator will explain the research study 
to the participant in terms suited to the participant’s comprehension and  answer any questions 
that may arise. Investigator should explain their rights as research participants, study 
procedures, risk and benefits, anticipated adverse effects.  Participants will have the 
opportunity to carefully review the written consent form and ask questions prior to signing. 
ICF should be signed prior to any interventions for the study. Participants must be informed 
that participation is voluntary and that they may withdraw from the study at any time, without 
prejudice. Participant will be g iven a copy of the signed consent form and the original consent 
form will be kept as a permanent record. Obtaining ICF should be documented in the source 
document.  
 
8.2 Institutional Review Board Approval  
The Sponsor/Investigator will obtain prospe ctive appro val of the clinical protocol and 
corresponding informed consent form(s) , and any other written information to be provided to 
the participants from Institutional Review Board (IRB). Additionally, any modifications to the 
clinical protocol and corresponding informed consent forms, and advertisements (i.e., directed 
at potential research subjects) for study recruitment  also requires IRB approval .   
The only circumstance in which a deviation from the current IRB -approved c linical 
protocol/consent forms  may be i nitiated in the absence of prospective IRB approval is to 
eliminate an apparent immediate ha zard to the research subject .  In such circumstances, the 
Sponsor/ Investigator will promptly notify the IRB of the deviation.  
The Sponsor/Investigator has to opera te in compliance with FDA regulations at 21 CFR Parts 
50 and 21 CFR 56, and in conformance with applicable International Conference on 
Harmonization (ICH) Guidelines on Good Clinical Practice (CGP).  
In the event of modification of the protocol  the sponsor/i nvestigator will submit (i.e., in 
advance  of implementing the change) a p rotocol amendment to the IND describing any change 
to the  protocol that significantly affects the safety of subjects, the scope of the investigation, or 
the scientific qualit y of the study.  Examples such changes requiring a protocol a mendment 
include:  
 Any increase in drug dosage or duration of exposure of individual subjects to the 
investigational drug beyond that described in the current protocol, or any significant 
increase  in the number of subjects under study.  
 Any significant change in the design of the protocol (such as the addition or deletion of 
a control group).  
 The addition of a new test or procedure that is intended to improve monitoring for, or 
reduce the risk of, a  side effect or adverse event; or the dropping of a test intended to 
monitor the safety of the investigational drug.  
 
8.3 Case Report Forms (CRFs)  
The Principal  Investigator and/or appropriate designated staff, will prepare CRFs, and maintain  
adequate and accurate participant case histories with observations and data pertinent to the 
study.  Study specific CRFs will document safety and treatment outcomes for safety monitoring 
and data analysis.  All study data will be entered into standardized  eCRFs in accordance with 
the study calendar, using single data entry with a secure access account.  The Clinical Research 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 46 
 Team  will complete the CRFs as soon as possible upon completion of the study visit; the 
Investigator will review and approve the comp leted CRFs.  
The information collected on CRFs shall be identical to that appearing in original source 
documents.  Source documents will be found in the patient’s medical records maintained by 
study person nel.  All source documentation should be kept in se parate research folders for each 
patient.  
In accordance with federal regulations, the Investigator is responsible for the accuracy and 
authenticity of all clinical and laboratory data entered onto CRFs.  The PI will approve all 
completed CRFs to attest tha t the information contained on the CRFs is true and accurate.  
The Principal Investigator will be responsible for ensuring the accurate capture of study data.  
At study completion, when the CRFs have been declared to be complete and accurate, the 
database will be locked.  Case report forms (CRFs) should  capture information on all immune -
mediated adverse events, i.e.:  
a) The criteria (under case definitions) which resulted in classification of an AE as an  
immune -mediated adverse reaction  
b) The treatment adm inistered, including specific drugs, doses, and duration of 
immunosuppressive treatment  
c) Information on dose modifications of, to include date when dose is modified, date dosing is 
resumed, and drug dose if reductions occur.  
 
8.4 Confidentiality and Privacy  
Participant’s identification is concealed and a number is used as the identifier instead of the 
patient’s name.  Patients will be informed of the extent to which their confidential health 
information generated from this study may be used for research purpo ses. Following the 
discussions, participants will be asked to sign HIPAA form and informed consent documents. 
The original signed document will become part of the patient’s medical records, and each 
patient will receive a copy of the signed document. Some designated research staff involved in 
the trial will have access to data. Therefore, the study protocol, documentation, data, and all 
other information generated will be held in strict confidence.   No information concerning the 
study or the data will be re leased to any unauthorized third party without prior written approval 
of the sponsor . 
 
8.5 Conflict of Interest  
The independence of this study from any actual or perceived influence, such as by the 
pharmaceutical industry, is critical.  Therefore, any actual c onflict of interest of persons who 
have a role in the design, conduct, analysis, publication, or any aspect of this trial will be 
disclosed and managed. Furthermore, persons who have a perceived conflict of interest will be 
required to have such conflicts managed in a way that is appropriate to their participation in 
the design and conduct of this trial.  
 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 47 
 9. SAFETY REPORTIN G 
9.1 Definitions  
An adverse event (AE)  is defined as any untoward medical  occurrence  associated with the 
use of a drug that occurs during the course of the clinical trial whether or not the event is 
considered related to the treatment or clinically significant.  
For this clinical trial, AEs will include any events reported by the patient, any new medical 
conditions, symptoms, any new abnormal fi ndings on physical examination or laboratory 
evaluation. Additionally, any worsening of a pre -existing condition or abnormality will also be 
considered as an AE.  
AEs will be collected by the investigator from Informed Consent Form  signed  through  30 days 
after the last dose of study medication , or prior to initiate of new anti -cancer therapy whichever 
is earlier .  AEs that occur outside of  30 days, following cessation of the study treatment, must 
also be reported within the same timeframe  if considered rel ated to study medication or 
procedure . All AEs must be recorded on CRF/eCRF. All AEs must be followed return to 
baseline or stabilizes.  
 
Serious adverse events (SAE):  
A serious adverse event is defined as any adverse experience that meets any of the follow ing 
criteria:  
 Results in death;  death due to disease progression is not considered as SAE.   
 Is life -threatening  
 Requires hospitalization or prolongation of existing hospitalization. Additionally, 
complications occurring during hospitalization are also considered AEs.  
 Results in persistent or significant disability or incapacity (This definition is not intended 
to include experiences of relatively minor medical significance such as uncomplicated 
headache, nausea, vomiting, diarrhea, influenza, or accidental trauma (e.g., sprained ankle) 
which may interfere or prevent everyday life functions but do not constitute a su bstantial 
disruption.);  
 Consists of a congenital anomaly or birth defect  
 Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical judgment, 
they may jeopardize the patient or subject and may require medical or surgical intervention 
to prevent one of the outcomes listed in this definition.  
 
9.2 Causality AE  
Causality assessment has become a common routine procedure in pharmacovigilance. 
Causality asses sments can decrease disagreement between assessors, classify relationship 
likelihood and improvement of scientific evaluation.  
 Limitations of causality assessment are following:  
 It can NOT assess accurate quantitative measurement of relationship likelihoo d 
 It can NOT distinguish valid from invalid cases  
 It can NOT prove the connection between drug and event  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 48 
  It can NOT quantify the contribution of a drug to the development of an adverse event  
All adverse events (AEs) must have their relationship to study intervention assessed by the 
clinician who examines and evaluates the participant based on temporal relationship and his/her 
clinical judgment. The degree of certainty about causality will be graded using the 2 categories 
below. In a clinical trial, the st udy product must always be suspect.  
 Related :  The AE is known to occur with the study product , there is a reasonable 
possibility that the study product  caused the AE, or there is a temporal relationship 
between the study product  and event. Reasonable possi bility means that there is 
evidence to suggest a causal relationship between the study product  and the AE.  
 Not Related :  There is not a reasonable possibility that the administration of the 
study product  caused the event, there is no temporal relationship between the study 
product  and event onset, or an alternate etiology has been established.  
 
 
Protocol Deviation  
Any change, divergence, or departure from the IRB -approved research protocol.   
 
Non-compliance  
The failure to comply with applicable IRB and other regulatory requirements , or regulatory 
requirements for the protection of human research subjects.  
 
Unanticipated Problem  
Any incident, experience, or outcome that:  
 Is unexpected in terms of nature, severity, or frequency in relation to  
(a) the research risks that are described in the IRB -approved research protocol and informed 
consent document; Investigator’s Brochure or other study documents, and  
(b) the characteristics of the subject population being studied; AND  
 Is related or possibly related  to participation in the research; AND  
 Suggests that the research places subjects or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or 
recognized.  
 
9.3 Categorizations of AEs  
All AEs a nd clinically significant laboratory abnormalities will be graded according to 
Common Terminology Criteria for AEs, Version 4.03 dated 14 June 2010. For any term that is 
not specifically listed on the CTCAE scale, intensity will be assigned a grade of 1 th rough 5 
using the following CTCAE guidelines:  
Grade1:  Mild; asymptomatic or mild symptoms, clinical or diagnostic observations only; 
intervention not indicated.  
Grade2:  Moderate; minimal, local or non -invasive intervention indicated; limiting age - 
appropriate instrumental activities of daily living.  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 49 
 Grade3:  Severe or medically significant but not immediately life -threatening; hospitalization 
or prolongation of hospitaliz ation indicated; disabling; limiting self -care activities of daily 
living.  
Grade4 : Life -threatening consequences; urgent intervention indicated.  
Grade5 : Death related to AE.  
 
9.4 Reporting of SAEs  
Any SAE, including death resulting from any cause, which occur s to any subject participating 
in this study must be reported to sponsor ( and/or IRB as required) within 24 hours  of first 
becoming aware of the SAE. SAEs will be collected by the investigator from Informed Consent 
Form  signed  through 90 days after the last dose of study medication , or prior to initiat ion of 
new anti -cancer therapy , whichever is earlier . SAEs that occur outside of  90 days, following 
cessation of the study treatment, must also be reported within the same timefra me, if considered 
related to study medication or procedure . Any SAE that is judged by the investigator to be 
related to the study medication must be reported regardless of the amount of time since the last 
dose received. Follow -up information collected for  any initial report of an SAE must also be 
reported to the sponsor (or its designee) within 24 hours of receipt by the investigator. All SAEs 
will be followed until resolution, stabilization of condition, or until follow -up is no longer 
possible.  
To fully understand the nature of any SAE, obtaining follow -up information is important. 
Whenever possible, relevant medical records such as discharge summaries, medical 
consultations, reports of radiographic studies, and clinical laboratory reports should be obtai ned.  
In the event of death, regardless of cause, all attempts should be made to obtain the death 
certificate and any autopsy report, if performed. These records should be reviewed in detail, 
and the investigator should comment on any event, lab abnormalit y, or any other finding, noting 
whether it should be considered a serious or non -serious AE, or whether it should be considered 
as part of the subject’s history. In addition, all events or other findings determined to be SAEs 
should be identified on the fo llow-up SAE form and the investigator should consider whether 
the event is related or not related to study drug. All events determined to be non -serious should 
be reported on the eCRF.  
 
9.5 IRB Reporting  
The investigators will report to the IRB the following a ccording to the requirements of 
reviewing IRB:  
 All SAEs, except deaths due to progressive disease  
 Non-compliance to GCP or protocol deviations as required by IRB  
IND Safety Reports and any unexpected incidences or problems during the trial may be also 
reportable to the IRB as per IRB requirement.  
 
9.6 Reporting of Pregnancy  
  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 50 
 For pregnancy including female subject pregnancy and male subject ’s female partner 
pregnancy, the investigator shall complete Pregnancy Report Form and submit the report to 
Innovent/ In novent representative within 24 hours of the aware of pregnancy.   
Maternal exposure  
If a female subject becomes pregnant during the course of the study or within 120 days of the 
last dose of IBI308, the treatment must be discontinued immediately. The investigator or 
other site personnel must inform the appropriate Innovent representatives  immediately but no 
later than 24 hours of when he or she becomes aware of it. The designated Innovent 
representative works with the investigator to ensure that all relevant information should be 
provided to the Innovent. Pregnancy is not regarded as an AE , however  ectopic pregnancy, 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomaly [in a 
live born, a terminated fetus, an intrauterine fetal demise, or a neonatal death must be 
reported and handled as SAEs. The outcome of all pregn ancies (spontaneous miscarriage, 
elective termination, ectopic pregnancy, normal birth, or congenital abnormality) and normal 
birth/ congenital abnormality must be followed up 60 days after outcome of pregnancy, all 
related information should be documented  even if the subject was discontinued from the 
study.   
Paternal exposure   
If a male subject ’s female partner becomes pregnant during the course of the study or within 
120 days of the last dose of IBI308, The subject continued the treatment. Pregnancy of m ale 
subject’s female partner is not considered to be an AE. However, ectopic pregnancy, 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomaly [in a 
live born, a terminated fetus, an intrauterine fetal demise, or a neonatal death must be 
reported and handled as SAEs. The outcome of all pregnancies (spontaneous miscarriage, 
elective termination, ectopic pregnancy, normal birth, or congenital abnormality) and normal 
birth/ congenital abnormality must be followed up 60 days afte r outcome of pregnancy, all 
related information should be documented even if the subject was discontinued from the 
study.   
Related information about a pregnancy from the partner of a male subject should be 
captured. If so, the male subject’s partner conse nt must be obtained to collect information 
related to the pregnancy and outcome; the male subject should not be asked to provide this 
information. A consent form specific to this situation must be used.   
 
10. STATISTICAL  CONSIDERATIONS AND EVALUATION OF RESUL TS 
10.1 General Statistical Consideration  
Descriptive statistics will be utilized for all safety, efficacy, immunogenicity, and 
pharmacokinetic parameters. Data will be summarized using descriptive statistics (number of 
subjects, mean, median, standard deviatio n, minimum, and maximum) for continuous variables 
and using frequencies and percentages for discrete variables. Time -to-event variables will be 
summarized using Kaplan -Meier methods and figures for the estimated median time. All data 
collected will be pres ented in subject listings. All data will be summarized by investigational 
drug dose level received . ORR will be calculated based on the full analysis set (FAS), including 
all patients who rec eived at least one dose of drug.  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 51 
  
10.2 Data Analysis  
 
10.2.1  Pharmacokinetic Data  
PK parameters will include, but not be limited to, AUC, C max, Cmin trough , t1/2, CL, and V ss. 
The concentration -time data will be summarized by descriptive statistics (n, mean, 
standard deviation, coefficient of variation, median, minimum, maximum, and geometric 
mean). PK parameters will be  estimated usi ng a non -compartmental method with 
WinNonlin (Pharsight Corp, Cary, North Carolina). Individual and mean serum 
concentration of investigational drug  versus time data will be tabulated and plotted by dose 
level.   
 
10.2.2  Immunogenicity  
 
All samples will first be analyzed for ADAs in a screening assay. Study samples with results 
below the screening cut -off will be reported as negative for ADAs. In the event of a positive 
result in the screening assay, samples will be analyzed in the confirmatory assay. All samples 
confirmed positive will be reported as p ositive, and wi ll be analyzed for presence of 
neutralizing antibodies (nAb) .  
 
The incidence of ADA will be summarized for all subjects who received at least one 
administration of investigational drug. Impact of ADAs on PK, efficacy/safety of 
investigational drug will be evaluated, if applicable.    
 
10.2.3  Efficacy  
ORR and the associated 2 -sided 95% exact confidence limits will be provided. The proportion 
of subjects who have experienced best response as CR, PR, SD or disease progression ( PD) 
will be calculated. PFS and OS data will be analyzed by Kaplan -Meier method . 
 
10.3 Determination of Sample Size  
For cohort 2: Assuming  the true ORR in advanced/metastatic endometrial cancer  patients 
receiving IBI308 is 25%, there is an approximately 80% chance to observe 8 or more than 8 
responders in a total of 40 patients (i.e. obse rved ORR≥20%). With observing at least 8/40 
responders, this study will approximately 96% confidence to exclude ORR≤10%.  A 
preliminary evaluation of efficacy will be conducted after approximately 20 evaluable patients 
with at least post baseline 2 tumor as sessments. If overwhelming efficacy is observed, this 
cohort might be further expanded beyond planned 40 patients to confirm the efficacy observed.  
 
10.4 Subject Replacement Policy  
In this study subject replacement is not permitted.  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 52 
  
10.5 Safety Evaluations  
Safety will be assessed by physical examinations, vitals, ECG, laboratory tests, AE monitoring, 
and concomitant  medication u sage monitoring  (see Schedule of Events) . AEs are graded 
according to the CTCAE v4.03. Investigators will report whether an AE is potential ly immune 
related (irAE). irAEs are defined as AEs of unknown etiology potentially associated with an 
immune phenomenon. Follow up for SAEs assessed as at least possibly related late irAEs will 
occur until 3 months after the last dose of IBI308. The overal l safety of IBI308 will be assessed 
by the Safety Monitoring Committee (SMC). SMC will be responsible for safety oversight, 
dose-escalation decisions, and other critical study decisions. Adverse events will be coded 
using the Medical Dictionary for Regulat ory Activities (MedDRATM).  
 
10.6 Efficacy Evaluations  
Tumor assessment will be performed at baseline, every 2 cycles  thereafter, and at the end of 
treatment by the investigator per RECIST v1.1 (Appendix 11.2). Efficacy evaluations will 
include the following: CT /MRI, physical examination, and other procedures as necessary. 
Adequate/preferred imaging assessments include high resolution CT with contrast or contrast -
enhanced MRI for evaluating radiographic tumor response. In subject with known severe 
contrast allerg ies, where pre -medication is not an option a non -contrast scan will suffice.  
Appearance of new malignant lesions denotes disease progression during the consistent 
scanning techniques.  If a patient is classified as having disease progression at a post -baseline 
tumor assessment, then confirmation by a second scan in the absence of rapid clinical 
deterioration is required. If a lesion is identified on during the study in an anatomical location 
that was not scanned at baseline is will be considered as a new l esion and will indicate disease 
progression.  Treatment response will also be assessed by iRECIST v1.1 criteria to assess the 
potential for pseudo progression.  
Anti-cancer activity parameters that will be assessed include determination of the following:  
1) Best overall response [complete response (CR), partial response (PR), stable disease 
(SD), or progressive disease]  
2) Objective response rate (ORR) (CR + PR)  
3) Duration of response (DOR) or duration of SD  
4) Disease control rate (DCR) (CR, PR or SD)  
5) Progression -free survival (PFS) and overall survival (OS) efficacy Evaluations  
 
10.7 Population Analysis  
 
10.7.1  Safety Population  
The safety analyses population will include all subjects who receive at least one dose of the 
investigational drug. The safety analyses population will be the primary population for 
evaluating treatment administration, compliance and safety in the study.  
 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 53 
 10.7.2  Efficacy Population  
The efficacy population will include all subjects who complete at least 1 cycle of treatment  and 
have at least 1 post baseline tumor assessment of efficacy or discontinue study early due to 
progressive disease.  
 
10.7.3  PK Population  
The PK population will include all subjects who have at least one blood sample providing 
evaluable PK data.  
 
10.8 Tabulation  of Individual Particip ation Data  
 
Data tabulations will summ arize the following  subject  numb ers: 
 Enrolled 
 Investigational drug treatment do se received 
 Evaluable for safety and efficacy 
 Protocol viol ations  
 Protocol compl etions  
 Withdraw from stu dy due to: 
 Adverse  event  
 Physician’s recomm endation 
 Withdrew consent 
 Lost to Follow -up 
Other reasons as collected on the  case report form.  
 
11. STUDY MANAGEMENT   
  
11.1 Quality Assurance and Quality Control  
  
Quality control (QC) procedures will be implemented to assure that any missing data will be 
communicated with sites for clarification and resolution.  
  
Standard Operating Procedures (SOPs) should be available to monitors. Monitors will verify 
that all the  clinical trial procedures are conducted, documented and reported in compliance 
with the protocol, ICH, GCP, GLP, GMP and other applicable regulatory requirements.  
  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 54 
 The investigational site will provide direct access to all trial related sites, source 
data/documents, and reports for the purpose of monitoring and auditing by the sponsor, and 
inspection by local and regulatory authorities.  
  
11.2 Clinical Monitoring Plan  
  
Monitors are qualified by training and experience to monitor the progress of clinical tr ials. 
Personnel monitoring this study will not be affiliated in any way with the trial conduct  
  
Site monitoring is conducted to ensure that the rights and well -being of trial participants are 
protected, that the reported trial data are accurate, complete , and verifiable, and that the 
conduct of the trial is in compliance with the currently approved protocol/amendment(s), 
with ICH GCP, and with applicable regulatory requirements.  
  
A sponsor representative will meet with the investigator and his/her staff  prior to the entrance 
of the first subject to review study procedures and methods of recording study data. After 
enrollment of the first subject, a sponsor representative will be assigned to periodically 
monitor each investigator site for study progress a nd to verify that standards of Good 
Clinical Practice (GCP) and/or ICH guidelines were followed.  
  
The investigator is expected to prepare for the monitor visit, ensuring that all source 
documents, completed CRFs, signed consent forms and other study rela ted documents are 
readily available for review.  
  
As a sponsor for clinical trials, FDA regulations require the Investigators to facilitate 
monitoring process. Monitors will evaluate adherence to the protocol, regulations, SOPs, 
human subject protection, study data, specifically data that could affect the interpretation of 
primary study endpoints. This is done through independent verification of study data with 
source documentation focusing on:  
● Informed consent process  
● Eligibility confirmation  
● Drug administration and accountability  
● Adverse events monitoring  
● Response assessment  
● Safety Monitor  
  
11.3 Study Closure  
  
The investigator may terminate the study at any time in the interest of subject welfare. The 
sponsor may terminate the study prematur ely at any time. Reasons for the closure of an 
investigational site or termination of a study may include:  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 55 
 ● The Investigator fails to comply with the protocol or ICH/GCP guidelines  
● Safety concerns  
● Inadequate recruitment of subjects by the investigator  
● Completion of the study  
  
If the clinical study is prematurely terminated or suspended, the sponsor or CRO 
representative will inform the investigator and the regulatory authorities of the termination/ 
suspension and the reasons for the termination/suspens ion as appropriate. The investigator 
should promptly notify the IEC/IRB of the termination or suspension and provide reasons. 
The sponsor reserves the right to close the investigational site or terminate the study in its 
entirety at any time, for reasonabl e cause.  
  
Premature termination of the study by either PI or sponsor will be governed under the terms 
of the contract between both parties.  
 
  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 56 
 12. REFERENCES  
 
KEYTRUDA® [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 
2014.  
 
OPDIVO® [package insert].  Princeton, NJ: Bristol -Myers Squibb Company: 2014  
 
FoundationOne CDx™  Technical Information, Cambridge, MA: Foundation Medicine, Inc. 
n.d 
 
American Cancer Society (ACS).   About Endometrial Cancer . February 29, 2016. 
https://www.cancer.org/content/dam/CRC/PDF/Public/8609.00.pdf . Accessed  December 
15 2017.  
 
Lee WL, Yen MS, Chao KC, Yuan CC, Ng HT, Chao HT, Lee FK, Wang PH. Hormon e 
therapy for patients with advanced or recurrent endometrial cancer. J Chin Med Assoc. 
2014 May;77(5):221 -6. doi: 10.1016/j.jcma.2014.02.007. Epub 2014 Mar 30.  
 
Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 
human  cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 
2017 Apr 19;9(1):34. doi: 10.1186/s13073 -017-0424 -2. 
 
Carbone DP, Reck M, Paz -Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel 
MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, 
Minenza E, Wrangle JM, Rodriguez -Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz 
LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen 
AC, Socinski MA; CheckMate 026 Investigator s. First -Line Nivolumab in Stage IV or 
Recurrent Non -Small -Cell Lung Cancer. N Engl J Med. 2017 Jun 22;376(25):2415 -2426. 
doi: 10.1056/NEJMoa1613493.  
 
Goodman AM1, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, 
Daniels GA, Kurzrock R. T umor Mutational Burden as an Independent Predictor of 
Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017 
Nov;16(11):2598 -2608. doi: 10.1158/1535 -7163.MCT -17-0386. Epub 2017 Aug 23.  
 
Rosenberg JE, Hoffman -Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et 
al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who 
have progressed following treatment with platinum -based chemotherapy: a single -arm, 
multicentre, phase 2 trial. Lancet. 2016; 387:1909 –20. 
 
 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 57 
 13. GENERAL APPENDICES  
13.1 Appendix 1 Eastern Cooperative Status Oncology Group Performance Status 
Score  
ECOG Performance Status Scale  
Grade  Descriptions  
0 Normal activity  
Fully active, able to carry on all pre -disease performance without restriction  
1 Symptoms, but ambulatory  
Restricted in physically strenuous activity, but ambulatory and able to carry out 
work of a light or sedentary nature ( e.g., light housework, office work)  
2 In bed <  50% of the time  
Ambulatory and capable of all self -care, but unable to carry out any work 
activities  
Up and about more than 50% of waking hours  
3 In bed >  50% of the time  
Capable of only limited self -care, confined to bed or chair more than 50% of 
waking hours  
4 100% bedridden  
Completely disabled  
Cannot carry on any self -care 
Totally confined to bed or chair  
5 Dead  
 
  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 58 
 13.2 Appendix 2 Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1  
Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1  
Measurable 
Tumor Burden  A maximum of 5 target  lesions  in total (and up to 2 per organ) can be identified at 
baseline and measured  through the course of therapy.  
Minimum Size of  
Measurable 
Lesions  ≥10 mm in longest diameter (LD) and 2X the slice thickness for extranodal lesions.  
≥15 mm in short axis diameter (SAD) for nodal lesions.  
≥10 mm in LD for clinical lesions (must be measured using electronic calipers).  
≥20 mm in LD for chest X -ray (if clearly defined and surrounded by aerated lung); CT is 
preferable.  
Ultrasound (US) canno t be used to measure lesions.  
Lymph Nodes  Lymph nodes are considered pathologically enlarged if >10 mm in SAD. To be 
measurable, nodal lesions must be ≥15 mm in SAD.  
Nodal lesions with SAD >10 mm and <15 mm are non - measurable.  
The sum of the diameters (LD for extranodal target lesions, SAD for nodal lesions) is 
followed through the course of therapy.  
Bone Lesions  A lytic or mixed lytic -blastic  bone lesion with a soft tissue component assessed on 
CT/MRI can be measurable if the minimum size criteria are met.  
Blastic bone lesions and bone lesions assessed on bone scan, positron emission therapy 
(PET) or plain films are non -measurable.  
Cystic  Lesions Lesions that meet the criteria for radiographically defined simple cysts are not 
malignant.  
Cystic lesions thought to be metastases can be measurable if they meet the minimum 
size criteria. Non -cystic lesions are preferable.  
Lesions  with  
Prior  Local  
Treatment 
Too Small To 
Measure  Lesions  in previo usly irradiat ed areas (or areas treated with local  thera py) are not 
measurable  unless the lesion has progre ssed since therapy.  
If a target  lesion  becomes too small to measure,  a default value of 5 mm is assigned. If 
the lesion  disappears,  the measur ement is recor ded as 0 mm. 
Lesions  That 
Split  or Coalesce  If extran odal target  lesions fragment, the LDs of the fragmented  portions  are added  to 
calculate  the sum. 
If target  lesions coalesce  and cannot  be disting uished, the LD of the coalesced  lesion  
is added to the sum. 
Defini tion of 
Complete  
Response  (CR)  CR requires  the disappearance  of all extranodal  lesions,  the regression  of all nodal  
lesions  to <10 mm SAD  and the normalization  of tumor  marker  level.  
Definition  of 
Progressive  
Disease  (PD)  PD is assessed  if the sum of the diameters  has increased  by ≥20% and ≥5 mm from  
nadir  (including  baseline  if it is the small est sum).  Patients  with measurable  disease:  
for "unequivocal  progression"  based  on non- target  disease,  there  must  be an overall  
level  of substantial  worsening that  merits  discontinuation  of therapy  (if target  disease  
is SD/PR).  Patients  without  measurable  disease:  for "unequivocal  progression"  of 
non-target  disease,  the increase  in overall  tumor  burden  must  be comparable  to the  
increase required  for PD of measurable  disease.  
Assessment  of 
New  Lesions  New lesions  should  be unequivocal  and not attributable  to differences  in scanning  
technique  or findings  which  may not be tumor  (ie, 'new' bone  lesions  may be healing  
or flare of pre- existing lesions).  If on is equivocal,  repeat scans  are needed  to confirm.  
If confirmed,  PD is assessed  at the date of the initial  scan.  Lesions  identified  in 
anatomic  locations  not scanned  at baseline  are considered  new.  New  lesions  on US 
should  be confirmed  on CT/MRI.  
FDG-PET  New lesions  can be assessed  using  FDG-PET:( -) PET at baseline  and (+) PET at 
follo w-up is PD  based  on a new lesion.  No PET at baseline  and (+) PET at follo w-up 
is PD if the new lesion  is confirmed  on CT. If a subsequent  CT confirms  the new lesion,  
the date of the PD is the date of the initial  PET scan.  No PET at baseline  and (+) PET 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 59 
 at follo w-up corresponding  to pre-existing  lesion  on CT that is not progressing;  not PD. 
Recurrence  of 
Lesions  For a patient  with SD/PR,  a lesion  which  disappears  and then reappears  will 
continue  to be measured  and added  to the sum.  Response  will depend  upon  the status  
of the other  lesions.  For a patient  with CR, reappearance  of a lesion  would  be 
considere d PD. 
  
Overall 
Response  One overall response table integrates target, non -target and new lesions and  
another table integrates non -target and new lesions for the assessment of subjects 
without measurable disease.  
Confirmation of 
Response  Confirmation of PR/CR is ONLY required for non -randomized trials where  
response is the primary endpoint. In these trials, subsequent confirmation of PR  
with one interim timepoint of SD is acceptable.  
 
Link:   
https://www.sciencedirect.com/science/article/pii/S0959804908008733/pdfft?md5=14893671e2bb1311c1f
e32 ab44638208&pid=1 -s2.0-S0959804908008733 -main.pdf   
 
  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 60 
 13.3 Appendix 3 modified RECIST 1.1 for immune based therapeutics (iRECIST)   
iRECIST Response Assessment  
Overall response will also be assessed using iRECIST. Immunotherapeutics may result in 
infiltration of immune cells leading to transient increase in the size in malignant lesions, or 
undetectable lesions becoming detectable. The criteria are identical to tho se of RECIST 1.1 in 
many respects but have been adapted to account for instances where an increase in tumour 
burden, or the appearance of new lesions, does not reflect true tumour progression.  
Key differences are described below. All responses defined usin g iRECIST criteria are 
designated with a prefix. iRECIST time -point and best overall responses will be recorded 
separately.  
Confirming Progression  
Unlike RECIST 1.1, iRECIST requires the confirmation of progression and uses the terms 
iUPD  (unconfirmed progression) and iCPD (confirmed progression). Confirmatory scans 
should be performed at least 4 weeks, but no longer than 8 weeks after iUPD.  
iCPD is confirmed if further increase in tumour burden, compared to the last assessment, is 
seen as  evidenced by one or more of the following:  
 Continued increase in tumour burden (from iUPD) where RECIST 1.1 definitions of 
progression had been met (from nadir) in target, non -target disease or new lesions  
 Progression in target disease worsens with an inc rease of at least 5 mm in the 
absolute  value of the sum  
 Continued unequivocal progression in non -target disease with an increase in tumour  
burden  
 Increase in size of previously identified new lesion (s) (an increase of at least 5 mm 
in the  absolute value o f the sum of those considered to be target new lesions) or 
additional new  lesions.  
 RECIST 1.1 criteria are met in lesions types (target or non -target or new lesions) where  
progression was not previously identified, including the appearance of additional ne w 
lesions.   
If iUPD is not confirmed at the next assessment, then the appropriate response will be 
assigned (iUPD if the criteria are still met, but no worsening, or iSD, iPR or iCR if those 
criteria are met compared to  baseline). As can be seen in table 2, the prior documentation of 
iUPD does not preclude assigning iCR, iPR, or iSD in subsequent time -point assessments or 
as best overall response (BOR) providing that iCPD is not documented at the next assessment 
after iUP D. 
New lesions  
New lesions should be assessed and measured as they appear using RECIST 1.1 criteria 
(maximum of 5 lesions, no more than 2 per site, at least 10 mm in long axis (or 15 mm in 
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 61 
 short axis for nodal lesions), and recorded as New Lesions -Target ( NLT) and New Lesion -
Non-Target (NLNT) to allow clear differentiation from baseline target and non -target lesions.  
New lesions may either meet the criteria of NLT or NLNT to drive iUPD (or iCPD). 
However, the measurements of target lesions should NOT be inc luded in the sum of measures 
of original target lesions identified at baseline. Rather, these measurements will be collected 
on a separate table in the case record form.  
PD is confirmed in the New Lesion category if the next imaging assessment, conducted a t 
least 4 weeks (but not more than 8 weeks) after iUPD confirms further progression from 
iUPD with either an increase of at least 5 mm in the absolute value of the sum of NLT OR an 
increase (but not necessarily unequivocal increase) in the size of NLNT les ions OR the 
appearance of additional new lesions . 
Target  
Lesions*  Non-Target  
Lesions*  New 
Lesions*  Time Point Response  
No 
prior  
iUPD**  Prior iUPD**; ***  
iCR iCR No iCR iCR 
iCR Non-
iCR/Non -
iUPD  No iPR iPR 
iPR Non-
iCR/Non -
iUPD  No iPR iPR 
iSD Non-
iCR/Non -
iUPD  No iSD iSD 
iUPD with  
no change  
OR 
decrease  
from last  
TP iUPD with  
no change  
OR 
decrease  
from last  
TP Yes NA NLs confirms iCPD  if NLs were previously 
identified and increase in size (≥5 mm in 
SOM for NLT or any increase for NLNT) 
or number. If no change in NLs (size or 
number) from last TP, remains iUPD  
iSD，iPR，
iCR iUPD  No iUPD  Remains iUPD unless iCPD confirmed 
based in further  increase in size of NT 
disease (need not meet RECIST 1.1 criteria 
for unequivocal PD)  
iUPD  Non-
iCR/Non -
iUPD；iCR No iUPD  Remains iUPD unless iCPD confirmed 
based on:  
o further increase in SOM of at least 5 mm, 
otherwise remains iUPD  
iUPD  iUPD  No iUPD  Remains iUPD unless iCPD confirmed 
based on further increase in:  
o previously identified T lesion iUPD SOM 
≥5 mm and / or  
o NT lesion iUPD (prior assessment - need 
not be unequivocal PD)  
iUPD  iUPD  Yes iUPD  Remains iUPD unless iCPD confirmed 
based on furth er increase in:  
o previously identified T lesion iUPD ≥5 
mm and / or  
o previously identified NT lesion iUPD 
(need not be unequivocal) and /or  
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.   Date : 01/07/2019 
Protocol # CIBI308A102    V 6 
CONFIDENTIAL  
Page 62 
 o size or number of new lesions previously 
identified  
Non-
iUPD/PD  Non-
iUPD/PD  Yes iUPD  Remains iUPD unless iCPD  confirmed 
based on  
o increase in size or number of new lesions 
previously identified  
* Using RECIST 1.1 principles. If no PSPD occurs, RECIST 1.1 and iRECIST categories for CR, 
PR and SD would be the same. ** in any lesion category. *** previously identi fied in assessment 
immediately prior to this TP.  
 